CN1200703C - 戊酸衍生物的用途 - Google Patents
戊酸衍生物的用途 Download PDFInfo
- Publication number
- CN1200703C CN1200703C CNB001270885A CN00127088A CN1200703C CN 1200703 C CN1200703 C CN 1200703C CN B001270885 A CNB001270885 A CN B001270885A CN 00127088 A CN00127088 A CN 00127088A CN 1200703 C CN1200703 C CN 1200703C
- Authority
- CN
- China
- Prior art keywords
- acid
- chemical compound
- propyl group
- ethyl acetate
- hexane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 title claims description 40
- 241001597008 Nomeidae Species 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 146
- 150000003839 salts Chemical class 0.000 claims abstract description 44
- 239000002253 acid Substances 0.000 claims abstract description 21
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 19
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 32
- -1 2-penta sulfenyl valeric acid Chemical group 0.000 claims description 31
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 29
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 239000000460 chlorine Substances 0.000 claims description 19
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 18
- 229940005605 valeric acid Drugs 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 230000004770 neurodegeneration Effects 0.000 claims description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 10
- 230000001537 neural effect Effects 0.000 claims description 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 9
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 8
- YCYMCMYLORLIJX-UHFFFAOYSA-N 2-propyloctanoic acid Chemical compound CCCCCCC(C(O)=O)CCC YCYMCMYLORLIJX-UHFFFAOYSA-N 0.000 claims description 8
- 210000001130 astrocyte Anatomy 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 7
- RXGPYPPCEXISOV-UHFFFAOYSA-N 2-propylheptanoic acid Chemical compound CCCCCC(C(O)=O)CCC RXGPYPPCEXISOV-UHFFFAOYSA-N 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 6
- WAFIBXRRCGDBOG-UHFFFAOYSA-N 2-(2-cyclohexylethyl)pentanoic acid Chemical compound CCCC(C(O)=O)CCC1CCCCC1 WAFIBXRRCGDBOG-UHFFFAOYSA-N 0.000 claims description 5
- OKJLFQUSPSHLFH-UHFFFAOYSA-N 7-fluoro-2-propylheptanoic acid Chemical compound CCCC(C(O)=O)CCCCCF OKJLFQUSPSHLFH-UHFFFAOYSA-N 0.000 claims description 5
- DZKBVTMVMHTODK-UHFFFAOYSA-N 8-fluoro-2-propyloctanoic acid Chemical compound CCCC(C(O)=O)CCCCCCF DZKBVTMVMHTODK-UHFFFAOYSA-N 0.000 claims description 5
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 5
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 claims description 4
- DOIRJHXLDOQGNU-UHFFFAOYSA-N 2-cyclohexylpentanoic acid Chemical group CCCC(C(O)=O)C1CCCCC1 DOIRJHXLDOQGNU-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- 208000004020 Brain Abscess Diseases 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 201000009906 Meningitis Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000001118 alkylidene group Chemical group 0.000 claims description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims description 3
- OQGCQTYDIGLMQQ-UHFFFAOYSA-N 2-(2-methoxyethyl)pentanoic acid Chemical compound CCCC(C(O)=O)CCOC OQGCQTYDIGLMQQ-UHFFFAOYSA-N 0.000 claims description 2
- VXOWGOAKTRJAMM-UHFFFAOYSA-N 2-benzylpentanoic acid Chemical compound CCCC(C(O)=O)CC1=CC=CC=C1 VXOWGOAKTRJAMM-UHFFFAOYSA-N 0.000 claims description 2
- PBOAGSAJKWUFFI-UHFFFAOYSA-N 2-butoxypentanoic acid Chemical group CCCCOC(C(O)=O)CCC PBOAGSAJKWUFFI-UHFFFAOYSA-N 0.000 claims description 2
- UOSPKLLEFWSVQO-UHFFFAOYSA-N 2-cyclohexyl-2-methylpentanoic acid Chemical compound CCCC(C)(C(O)=O)C1CCCCC1 UOSPKLLEFWSVQO-UHFFFAOYSA-N 0.000 claims description 2
- GUTUMEOXDGSMNF-UHFFFAOYSA-N 2-hexoxypentanoic acid Chemical group CCCCCCOC(C(O)=O)CCC GUTUMEOXDGSMNF-UHFFFAOYSA-N 0.000 claims description 2
- QVYBDOFMASCXIC-UHFFFAOYSA-N 2-pentoxypentanoic acid Chemical group CCCCCOC(C(O)=O)CCC QVYBDOFMASCXIC-UHFFFAOYSA-N 0.000 claims description 2
- SFXXYKYOGGWUHX-UHFFFAOYSA-N 2-phenylpentanoic acid Chemical compound CCCC(C(O)=O)C1=CC=CC=C1 SFXXYKYOGGWUHX-UHFFFAOYSA-N 0.000 claims description 2
- OXCSLNZXEDCDTN-UHFFFAOYSA-N 5-ethyl-2-propylheptanoic acid Chemical compound CCCC(C(O)=O)CCC(CC)CC OXCSLNZXEDCDTN-UHFFFAOYSA-N 0.000 claims description 2
- KLVBBRCKPYZPRJ-UHFFFAOYSA-N 5-phenyl-2-propylpentanoic acid Chemical compound CCCC(C(O)=O)CCCC1=CC=CC=C1 KLVBBRCKPYZPRJ-UHFFFAOYSA-N 0.000 claims description 2
- PXDOFRSDSXMYEC-UHFFFAOYSA-N 6,6-dimethyl-2-propylheptanoic acid Chemical compound CCCC(C(O)=O)CCCC(C)(C)C PXDOFRSDSXMYEC-UHFFFAOYSA-N 0.000 claims description 2
- GYPWKLKNQKMTFC-UHFFFAOYSA-N 6-methyl-2-propylheptanoic acid Chemical compound CCCC(C(O)=O)CCCC(C)C GYPWKLKNQKMTFC-UHFFFAOYSA-N 0.000 claims description 2
- WEKWUDICXBNIAT-UHFFFAOYSA-N 7-chloro-2-propylheptanoic acid Chemical compound CCCC(C(O)=O)CCCCCCl WEKWUDICXBNIAT-UHFFFAOYSA-N 0.000 claims description 2
- QNRILMPZHFVUOI-UHFFFAOYSA-N 7-methyl-2-propyloctanoic acid Chemical compound CCCC(C(O)=O)CCCCC(C)C QNRILMPZHFVUOI-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract 1
- 230000006764 neuronal dysfunction Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 298
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 283
- 238000004809 thin layer chromatography Methods 0.000 description 80
- 239000000243 solution Substances 0.000 description 65
- 239000000203 mixture Substances 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 42
- 235000002639 sodium chloride Nutrition 0.000 description 42
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 41
- 241000239290 Araneae Species 0.000 description 39
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- 230000004044 response Effects 0.000 description 22
- 238000005406 washing Methods 0.000 description 22
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 20
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 20
- 210000002569 neuron Anatomy 0.000 description 19
- 238000010898 silica gel chromatography Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 238000003756 stirring Methods 0.000 description 18
- 238000001035 drying Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 12
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 12
- 229940084026 sodium valproate Drugs 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 230000003140 astrocytic effect Effects 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 239000000376 reactant Substances 0.000 description 10
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 238000005984 hydrogenation reaction Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 235000011121 sodium hydroxide Nutrition 0.000 description 8
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000003810 ethyl acetate extraction Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 206010018341 Gliosis Diseases 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 208000037875 astrocytosis Diseases 0.000 description 6
- 230000007341 astrogliosis Effects 0.000 description 6
- 230000003915 cell function Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 235000013922 glutamic acid Nutrition 0.000 description 6
- 239000004220 glutamic acid Substances 0.000 description 6
- 239000003701 inert diluent Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 210000004498 neuroglial cell Anatomy 0.000 description 6
- 239000003513 alkali Substances 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000003925 brain function Effects 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 5
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000001263 acyl chlorides Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- HNBDRPTVWVGKBR-UHFFFAOYSA-N n-pentanoic acid methyl ester Natural products CCCCC(=O)OC HNBDRPTVWVGKBR-UHFFFAOYSA-N 0.000 description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 229940070710 valerate Drugs 0.000 description 4
- 229960000604 valproic acid Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000003053 piperidines Chemical class 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N 1-nonene Chemical compound CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- BFSMWENDZZIWPW-UHFFFAOYSA-N Isopropamide iodide Chemical compound [I-].C=1C=CC=CC=1C(C(N)=O)(CC[N+](C)(C(C)C)C(C)C)C1=CC=CC=C1 BFSMWENDZZIWPW-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- BAZMYXGARXYAEQ-UHFFFAOYSA-N alpha-ethyl valeric acid Chemical compound CCCC(CC)C(O)=O BAZMYXGARXYAEQ-UHFFFAOYSA-N 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 150000001538 azepines Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 230000002575 demyelinative effect Effects 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- PBGGNZZGJIKBMJ-UHFFFAOYSA-N di(propan-2-yl)azanide Chemical compound CC(C)[N-]C(C)C PBGGNZZGJIKBMJ-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000004905 finger nail Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- BNSOYWDFFBDEFB-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O BNSOYWDFFBDEFB-UHFFFAOYSA-L 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical group CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical group CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 1
- ZSDQQJHSRVEGTJ-UHFFFAOYSA-N 2-(6-amino-1h-indol-3-yl)acetonitrile Chemical compound NC1=CC=C2C(CC#N)=CNC2=C1 ZSDQQJHSRVEGTJ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- ZXKAAVCEVXTAMD-UHFFFAOYSA-N 2-fluoro-2-propylpentanoic acid Chemical compound CCCC(F)(C(O)=O)CCC ZXKAAVCEVXTAMD-UHFFFAOYSA-N 0.000 description 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 1
- 101710115046 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- FLLHEJPVLSEJRX-UHFFFAOYSA-N C(CCC)OC(CCCCCC)(OCCCCCC)OCCCCC Chemical compound C(CCC)OC(CCCCCC)(OCCCCCC)OCCCCC FLLHEJPVLSEJRX-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KKCIOUWDFWQUBT-AWEZNQCLSA-N L-thyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 KKCIOUWDFWQUBT-AWEZNQCLSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- XPUJQEGMNQWMJI-UHFFFAOYSA-N OCC(=O)O.[Na] Chemical compound OCC(=O)O.[Na] XPUJQEGMNQWMJI-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- COGNCXJCCDGTDV-UHFFFAOYSA-N [O].N1C=CC=CC=C1 Chemical compound [O].N1C=CC=CC=C1 COGNCXJCCDGTDV-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 238000011938 amidation process Methods 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- QYVVUXPJFQZLSY-UHFFFAOYSA-N argon;n,n-diethylethanamine Chemical compound [Ar].CCN(CC)CC QYVVUXPJFQZLSY-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000219 ependymocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002461 excitatory amino acid Effects 0.000 description 1
- 239000003257 excitatory amino acid Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- QCZPJJIXHJSOMY-UHFFFAOYSA-N methyl 2-hydroxypentanoate Chemical compound CCCC(O)C(=O)OC QCZPJJIXHJSOMY-UHFFFAOYSA-N 0.000 description 1
- WPRYUWYMOZQHIY-UHFFFAOYSA-N methyl 2-propylpentanoate Chemical compound CCCC(CCC)C(=O)OC WPRYUWYMOZQHIY-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000008251 pharmaceutical emulsion Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 150000003021 phthalic acid derivatives Chemical class 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 1
- 229960001930 valpromide Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000002385 vertebral artery Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/19—Acids containing three or more carbon atoms
- C07C53/21—Acids containing three or more carbon atoms containing fluorine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/63—Halogen-containing esters of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
- C07C69/708—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
式(X)化合物及其无毒盐或酸加成盐可用于预防和治疗神经变性疾病(如Alzheimer病等)以及因中风或外伤引起的神经元机能障碍(如多发性硬化等)等各种病症,式(X)中R5,R6,R11和n均如说明书所述。
Description
本申请是申请号为CN94106203.1母案的分案申请。该母案的申请日为1994年6月1日;发明名称为“戊酸衍生物”。
本发明涉及戊酸衍生物,尤其是涉及:
(1)式(I)戊酸衍生物及其无毒性盐和酸加成盐:
其中所有代号如下述,
(2)含式(I)戊酸衍生物及其无毒性盐和酸加成盐作活性成分的脑功能改进剂,
(3)式(I)戊酸衍生物及其无毒性盐和酸加成盐制备方法以及
(4)含式(X)戊酸衍生物及其无毒性盐和酸加成盐作活性成分的脑机能改进剂:
其中所有代号如下述。
构成大脑的两个主要结构单元为神经元和神经胶质。神经元由细胞体与树突一起构成。沿体轴传输神经信息的分支结构和经其它神经元接收冲动的分支结构为目前已知的两种树突。神经信息经突触传播而从一个神经元传至另一个神经元,所谓突触是将两个连通神经元的树突紧密连起来的裂。
但是,神经胶质是补偿这些神经元机能的单元,其中通过提供营养素,去除分解产物/废物,保持适当的离子平衡并发挥其它有关的机能作用以使神经元正常发挥生理机能而补偿神经元的机能。神经胶质包括各种细胞。在中枢神经系统中有星形细胞,前突神经胶质细胞和小神经胶质细胞;在外周神经系统中有Schwann细胞和套细胞;而在室内皮中有室管膜细胞。
出生前后神经元立即生长和分化,而神经胶质的生长和分化甚至在出生后还持续进行。神经变性疾病的病理因素据认为主要归因于神经元的异常(神经变性疾病例如有Alzheimer病,多发性硬化,肝性脑病和延迟神经元坏死)。但是,最近注意力又集中在神经元周围的神经胶质,尤其是星形细胞的机能异常方面(Scientific American,pp 45-52,April 1989)。这是因为星形细胞不仅作为补偿细胞,而且这些细胞还可促进谷氨酸和γ-氨基丁酸(GABA)代谢,神经肽和细胞活素合成,并且除了在调节脑机能时发挥重要作用之外还可作免疫囊肿或神经元。因此,星形细胞异常可能是导致各种脑疾病的决定因素。
发生脑病时,由星形细胞衍生的活性或反应性星形细胞产生的活性星形细胞增生集中在神经元坏死的部位附近[J.Anat.,106,471(1970);Dev,Biol.,72,381(1979);Adv.Cell.Neurobiol.,2,249(1981)]。虽然导致脑损坏的活性星形细胞增生据认为是对神经元再生的代偿反应,但最近的举证又指出活性星形细胞增生的过度反应会触发神经变形蜕膜[Science,237,642(1987);Brain Res.,481,191(1989);Ibid,547,223(1991)]。从参与这种过度反应的活性星形细胞中可释放出各种神经递质和细胞活素[Cytobios.,61,133(1990)]。在这些物质中,最重要的是识别神经生长因子(NGF)[Biochem.Biophys.Res.Commun.,136,57(1986);Brain Res.,560,76(1991)]和β-淀粉样前体蛋白(β-APP)分泌[Neuron.,3,275(1988);J.Neurosci.Res.,25,431(1990);FEBS Lett.,292,171(1991)]。β-APP的表达已促使活性星形细胞作为可能的β-淀粉样蛋白源,并且因此已影响到β-淀粉样蛋白沉积和活性星形细胞增生之间的紧密关系[J.Neurol.Sci.,112,68(1992)]。β-淀粉样疫在诱发Alzheiner病(AD),代表性神经变性疾病方面起到了重要的作用[Proc.Natl.Acad.Sci.USA.,82,4245(1985);Brain Res.Reviews,16,83(1991);TIPS,12,383(1991)]。
以剂量/功效为基础,从活性星形细胞分泌出来的NGF引起的神经毒性要比β-淀粉样蛋白单独存在时的神经毒性高1.0×105倍,并且对β-淀粉样蛋白引起的神经元坏死显示出协同效应[Proc.Natl.Acad.Sci.USA,87,9020(1990)]。此外,β-淀粉样蛋白还会促进兴奋性氨基酸如谷氨酸和N-甲基-D-天冬氨酸(NMDA)引起的神经元坏死[Brain Res.,533,315(1990)]。因此,这些事实可能导致在AD中有关β-淀粉样蛋白的病理发现[Proc.Natl.Sci.USA,82,4245(1985);Brain Res.Reviews,16,83(1991)]。
最近的发现表明,在AD病人中已发现星形细胞机能异常。另外,已假定活性星形细胞与诱发AD直接相关[Neurol.,40,33(1990)]。
但是,还不清楚为什么活性星形细胞会过多地增生。本发明人因此研究了诱发活性星形细胞增生的各种因素,从而用来自新生鼠脑的初期培养星形细胞定义出这种内源要素的生理功能。按照常规培养方法培养来自身体去掉后脑的星形细胞,就会成功地诱发活性星形细胞生成。因此,除了体外5天(DIV)引发的细胞明显异常增生而外,还观察到活性星形细胞中神经胶质原纤维酸性蛋白(GFAP)含量提高和特殊的形态变化(增生)。
在获得上述发现并得到证实之后,再追踪诱发活性星形细胞生成期间出现的机能变化。结果并没有在活性星形细胞中显示出与电压有关的钙,钠和和钾通道以及谷氨酸受体反应方面的任何明显变化。但是,作为抑制性调节的GABAA受体反应消失伴随有培养物中星形细胞异常增生减弱。该反应降到一定程度,星形细胞生长就变得不可检测。根据对甘氨酸(抑制性氨基酸)没有引发任何受体反应这一观测结果,星形细胞的抑制性控制降低就可能诱发活性星形细胞生成。
总的说来,脑病发生时,伴随有星形细胞的GABAA受体反应消失。因为星形细胞持续出现异常,就有大量神经递质和细胞活素(尤其是NGF和β-APP)释放出来。这些超常事件会产生协同效应,进而可能导致神经元树突异常分支/延长并伴随神经元坏死。换句话说,随之突然发生神经变性疾病。
因此,提高活性星形细胞的GABAA受体反应可改进并重新设计出机能异常导致的神经变性疾病的治疗和或预防方法。
而且,在脑损伤时局部缺血神经元端部释放的过量谷氨酸和天冬氨酸会引起持续的去极化,进而可能导致有关神经元失效[NikkeiSci.J.,9,52(1992)]。这一事件会伴随有过量脑水肿和脑肿块(或星形细胞增生),并进而导致坏死。随着活性星形细胞的过量反应引发的神经毒性被抑制,就可改善星形细胞的GABAA受体反应。因此,这些事件不仅降低了局部缺血诱发的死亡率,而且还可缓解/治疗局部缺血后的脑机能障碍。
到目前为此,还未发现可防止GABAA受体反应消失的药物。
根据因星形细胞缺乏抑制性控制能力引起活性星形细胞的过量反应这一发现,本发明人尝试了用各种合成的抑制性化合物提高这些星形细胞的机能活性。结果,本发明人发现戊酸衍生物可有效地用于增强GABAA受体反应并且完成了本发明。
本发明式(I)化合物及其无毒性盐和酸加成盐均为新化合物。
在式(X)化合物中已知2-丙基戊酸,2-丙基戊酰胺,2-丙基己酸,2-丙基庚酸,2-丙基辛酸,2-丙基壬酸,2-丙基癸酸,5-甲基-2-丙基己酸,2-环己基戊酸,2-环己基戊酸甲酯,2-环己基戊酸乙酯,2-(2-环己基乙基)戊酸,2-(3-环己基丙基)戊酸,7-氟-2-丙基庚酸,8-氟-2-丙基辛酸,9-氟-2-丙基壬酸,5,5,5-三氟-2-丙基戊酸,2-氯-2-丙基戊酸,2-丙基-2-戊烯酸,2-丙基-3-戊烯酸,2-丙基-4-戊烯酸,2-乙基戊酸和2-乙基己酸。
例如,2-丙基戊酸称为丙戊酸,而2-丙基戊酰胺称为丙戊酰胺,并已用作抗癫痫药。还已知2-丙基-2-戊烯酸,2-丙基-3-戊烯酸和2-丙基-4-戊烯酸可作为丙戊酸的代谢产物,而2-乙基戊酸,2-乙基己酸和2-丙基己酸可作为丙戊酸的同系物[Neuropharmacology,24(5),427-435(1985)]。已公开5,5,5-三氟-2-丙基戊酸可作为抗癫痫药[JP Kokai Koho 6-116200]。从Chemical Abstracts Service已知以下化合物,但这些化合物未用作药物。这些化合物的公开号写在括号中:
2-丙基庚酸(31080-39-4)
2-丙基辛酸(31080-41-8)
2-丙基壬酸(65185-82-2)
2-丙基癸酸(123790-07-8)
5-甲基-2-丙基己酸(94072-28-3)
2-环己酸戊酸(106854-67-5)
2-环己基戊酸甲酯(102617-56-1)
2-环己基戊酸乙酯(22579-21-1)
2-(2-环己基乙基)戊酸(28396-40-9)
2-(3-环己基丙基)戊酸(15331-26-7)
7-氟-2-丙基庚酸(6863-43-0)
8-氟-2-丙基辛酸(3847-39-0)
9-氟-2-丙基壬酸(3847-35-6)
2-氯-2-丙基戊酸(143100-15-6)。
2-丙基辛酸和2-丙基壬酸已作为试剂销售。
到目前为止还不知丙戊酸对星形细胞的以下活性。
(1)抑制γ-氨基丁酸氨基转移酶(GABA-T)[Neuropharmacology,25,617(1986)]。
(2)导致神经胶质热休克蛋白表现为胶原蛋白类型IV受体[Brain Res.,459,131(1988)]。
(3)抑制神经胶质增加[Brain Res.,554,223(1991)]。
(4)降低接受GABA的亲合性[Neurochem.Res.,17,327(1992)]。
本发明人发现的抑制活性星形细胞诱导生成的作用目前还根本不为人所知。
根本不可能从以上已知的活性预知丙戊酸也具有抑制活性星形细胞诱导生成的活性。也就是说这是第一次发现式(X)化合物,包括2-丙基己酸,2-丙基庚酸,2-丙基辛酸,2-丙基壬酸,2-丙基癸酸,5-甲基-2-丙基己酸,2-环己基戊酸,2-环己基戊酸甲酯,2-环己基戊酸乙酯,2-(2-环己基乙基)戊酸,2-(3-环己基丙基)戊酸,7-氟-2-丙基庚酸,8-氟-2-丙基辛酸,9-氟-2-丙基壬酸,5,5,5-三氟-2-丙基戊酸,2-氯-2-丙基戊酸和2-丙基-2-戊烯酸具有抑制活性星形细胞诱导生成的活性。
本发明涉及新化合物,其制备方法及其用途以及已知化合物的新用途。
因此,本发明涉及
1)式(I)化合物及其无毒盐和酸加成盐。
其中R1为有1个碳原子被1-3个氟原子取代的C1-10烷基;
R2为羟基,C1-4烷氧基,被1个苯基取代的C1-4烷氧基或NR3R4,其中
R3和R4独立地代表
(i)氢,
(ii)C1-4烷基,
(iii)苯基,
(iv)被C1-4烷氧基或羧基取代的苯基,
(v)含1个氮原子的4-7元杂环或
(vi)被苯基取代的C1-4烷基,被C1-4烷氧基或羧基取代的苯基或含1个氮原子的4-7元杂环或R3和R4与其连接氮原子一起为含1或2个氮原子或1个氮原子和1个氧原子的4-7元饱和杂环或氨基酸残基;
只是R1不是F-(CH2)4-,F-(CH2)5-,F-(CH2)6-,F3C-CH2-,
2)含式(I)化合物,其无毒盐或其酸加成盐作为活性成分的脑机能改进剂,
3)式(I)化合物及其无毒盐和酸加成盐制备方法,
4)含式(X)化合物,其无毒盐或其酸加成盐的脑机能改进剂:
其中n为0或1;
R11为氢或氯;
R5为R7-CH2-或R8或
R5和R11一起为C3-10亚烷基;
R7为F-(CH2)m-,其中m为4-6,F3C-CH2-,被1或2个氯原子取代的C2-10烷基或被1或2个C1-4烷氧基,C3-7环烷基,苯基或苯氧基取代的C1-5烷基;
R8为
(i)C3-10烷基,
(ii)C3-10烯基,
(iii)C2-10烷氧基,
(iv)C2-10烷硫基,
(v)C3-7环烷基,
(vi)苯基或
(vii)苯氧基;
R6为羟基,C1-4烷氧基,被1个苯基取代的C1-4烷氧基或NR9R10,其中
R9和R10独立地代表
(i)氢,
(ii)C1-4烷基,
(iii)苯基,
(iv)被C1-4烷氧基或羧基取代的苯基,
(v)含1个氮原子的4-7元杂环或
(vi)被苯基取代的C1-4烷基,被C1-4烷氧基或羧基取代的苯基或含1个氮原子的4-7元杂环或R3和R4与其连接氮原子一起为含1或2个氮原子或1个氮原子和1个氧原子的4-7元饱和杂环或氨基酸残基。
式(I)中R1代表的有1个碳原子被1-3个氟原子取代的C1-10烷基指甲基,乙基,丙基,丁基,戊基,己基,庚基,辛基,壬基,癸基以及有1个碳原子被1,2或3个氟原子取代的这些基团的异构基团,并且所有这些基团都是优选的。尤其优选的基团是有1个碳原子被1-3个氟原子取代的C1-7烷基。
R2,R6代表的或在R3,R4,R9或R10中作为苯基取代基的C1-4烷氧基指甲氧基,乙氧基,丙氧基,丁氧基及其异构基团,所有这些基团都是优选的。而且优选R2或R6为羟基。
R3,R4,R9或R10代表的C1-4烷基指甲基,乙基,丙基,丁基及其异构基团。
R3,R4,R9或R10代表的含1个氮原子的4-7元杂环指吡咯,吡啶,吖庚因或其部分饱和环或完全饱和环(吡咯烷,哌啶等),所有这些环都是优选的。尤其优选的环为吡啶。
R3,R4及其连接氮原子或R9,R10及其连接氮原子代表的含1个氮原子的4-7元饱和杂环指氮杂环丁烷,吡咯烷,哌啶或全氢化吖庚因,所有这些环都是优选的。尤其优选的环为哌啶。
R3,R4及其连接氮原子或R9,R10及其连接氮原子代表的含2个氮原子的4-7元饱和杂环指吡唑烷,咪唑烷,全氢化二嗪(哌嗪等)或全氢化二氮杂_,所有这些环都是优选的。尤其优选的环为哌嗪。
R3,R4及其连接氮原子或R9,R10及其连接氮原子代表的含1个氮原子和1个氧原子的4-7元饱和杂环指噁唑烷,全氢化噁嗪(吗啉等)或全氢化氧氮杂_,所有这些环都是优选的。尤其优选的环为吗啉。
R3,R4及其连接氮原子或R9,R10及其连接氮原子构成的氨基酸残基指任何氨基酸残基。该氨基酸残基还包括其羧基转化成的酯。例如,这些氨基酸残基包括甘氨酸,丙氨酸,丝氨酸,半胱氨酸,胱氨酸,苏氨酸,缬氨酸,蛋氨酸,亮氨酸,异亮氨酸,正亮氨酸,苯丙氨酸,酪氨酸,甲状腺原氨酸,脯氨酸,羟基脯氨酸,色氨酸,天冬氨酸,谷氨酸,精氨酸,赖氨酸,鸟氨酸,组氨酸残基或其酯(C1-4烷基酯或苯甲基酯)。尤其优选的氨基酸为甘氨酸。
R7代表的C2-10烷基指乙基,丙基,丁基,戊基,己基,庚基,辛基,壬基,癸基及其异构基团,而R7代表的C1-5烷基指乙基,丙基,丁基,戊基及其异构基团。
在R7中作为C1-5烷基的取代基的C1-4烷氧基指甲氧基,乙氧基,丙氧基,丁氧基及其异构基团。R7代表的C3-7环烷基指环丙基,环丁基,环戊基,环己基和环庚基。
R8代表的C3-10烷基指丙基,丁基,戊基,己基,庚基,辛基,壬基,庚基及其异构基团,所有这些基团都是优选的。尤其优选的基团为C3-7烷基。
R8代表的C3-10烯基指丙烯基,丁烯基,戊烯基,己烯基,庚烯基,辛烯基,壬烯基,癸烯基及其异构基团,所有这些基团都是优选的。C2-10烷氧基指乙氧基,丙氧基,丁氧基,戊氧基,己氧基,庚氧基,辛氧基,壬氧基,癸氧基及其异构基团,所有这些基团都是优选的。C2-10烷硫基指乙硫基,丙硫基,丁硫基,戊硫基,己硫基,庚硫基,辛硫基,壬硫基,癸硫基及其异构基团,所有这些基团都是优选的。C3-7环烷基指环丙基,环丁基,环戊基,环己基和环庚基,所有这些基团都是优选的。
R5和R11代表的C3-10亚烷基指亚丙基,亚丁基,亚戊基,亚己基,亚庚基,亚辛基,亚壬基,亚癸基及其异构基团,所有这些基团都是优选的。
在本发明式(I)化合物中,实施例中所述化合物和以下化合物都是优选的。
(1)
FH2C-(CH2)6-
FH2C-(CH2)7-
FH2C-(CH2)8-
FH2C-(CH2)9-
F2HC-(CH2)6-
F2HC-(CH2)7-
F2HC-(CH2)8-
F2HC-(CH2)9-
F3C-(CH2)6-
F3C-(CH2)7-
F3C-(CH2)8-
F3C-(CH2)9-
(2)
R1 - R2
FH2C-(CH2)2- -NH2
″ -NHC2H5
″ -N(CH3)2
R1 - R2
F2HC-(CH2)4- -NH2
″ -NHC2H5
″ -N(CH3)2
在本发明式(X)化合物中,实施例中所述化合物和以下化合物都是优选的。
n R11 R5
0 H FH2C-(CH2)4-
0 H FH2C-(CH2)5-
0 H FH2C-(CH2)6-
0 H (H3C)2HC-(CH2)2-
0 H (H3C)2HC-(CH2)3-
0 H (H3C)2HC-(CH2)4-
0 H H3C-(CH2)4-O-
0 H H3CO-(CH2)4-
0 H H3C-(CH2)2-
0 H H3C-(CH2)5-
0 H H3C-(CH2)6-
0 Cl H3C-(CH2)2-
0 Cl H3C-(CH2)5-
0 Cl H3C-(CH2)6-
1 Cl FH2C-(CH2)4-
1 Cl FH2C-(CH2)5-
1 Cl FH2C-(CH2)6-
1 Cl (H3C)2HC-(CH2)2-
1 Cl (H3C)2HC-(CH2)3-
1 Cl (H3C)2HC-(CH2)4-
1 Cl H3C-(CH2)4-O-
1 Cl H3CO-(CH2)4-
1 Cl
1 Cl H3C-(CH2)2-
1 Cl H3C-(CH2)5-
1 Cl H3C-(CH2)6-
1 H H3C-(CH2)4-CH=
1 H H3C-(CH2)5-CH=
H3C-CH=CH-
1 H H2C=CH-(CH2)5-
1 H H3C-(CH2)2-
1 H H3C-(CH2)6-
R5 R6
″ -NH2
R5 - R6
H3C-(CH2)5- -N(CH3)2
R5 - R6
″ -NH2
″ -NHCH3
R5 - R6
″ -NH2
″ -NHCH3
R5 - R6
FH2C-(CH2)6-
″ -NH2
″ -NHCH3
R5 - R6
F3C-CH2- -NH2
″ -NHC2H5
″ -N(CH3)2
在本发明中可用每种活性成分或两种以上活性成分组合进行配方。
除另有说明而外,本发明还包括所有异构体。例如,烷基,烷氧基和烯基包括呈直链和支链的这些基团。烯基中的双键包括E,Z和EZ混合型。由不对称碳原子如支链烷基而产生的异构体也包括在本发明中。
本发明式(I)化合物中R2为羟基或式(X)化合物中R6为羟基的化合物可转化成相应的盐。无毒盐和水溶性盐是优选的。适宜盐的具体例子如下:
碱金属(钠,钾等)盐,碱土金属(钙,镁等)盐,铵盐,药用有机胺(四甲铵,三乙胺,甲基胺,二甲基胺,环戊基胺,苯甲基胺,苯乙基胺,哌啶,单乙醇胺,二乙醇胺,三(羟甲基)氨基甲烷,赖氨酸,精氨酸,N-甲基-D-葡糖胺等)盐。
式(I)和(X)的化合物还可转化成相应的酸加成盐。无毒盐和水溶性盐是优选的。适宜盐的具体例子如下:
无机酸如盐酸,氢溴酸,氢碘酸,硫酸,磷酸,硝酸盐;有机酸如乙酸,乳酸,酒石酸,苯甲酸,柠檬酸,甲磺酸,乙磺酸,苯磺酸,甲苯磺酸,isedthioatic酸,葡糖醛酸,葡糖酸盐。
优选本发明涉及式(X)化合物或其无毒盐或酸加成盐在制备预防和/或治疗活性或反应性星形细胞诱导的脱神经髓鞘病的药物方面的用途。更优选所述的化合物是7-氟-2-丙基庚酸,8-氟-2-丙基辛酸,9-氟-2-丙基壬酸,5,5,5-三氟-2-丙基戊酸,或者所述的化合物是2-丙基戊酸,2-丙基庚酸,2-丙基己酸,2-丙基癸酸,2-丙基辛酸,2-丙基壬酸,4-甲基-2-丙基戊酸,5-甲基-2-丙基己酸,7-甲基-2-丙基辛酸,6-甲基-2-丙基庚酸,5-乙基-2-丙基庚酸,5,5-二甲基-2-丙基己酸,6,6-二甲基-2-丙基庚酸,2-乙基己酸,2-氯-2-丙基戊酸,或者所述的化合物是7-氯-2-丙基庚酸,2-苯甲基戊酸,2-(3-苯基丙基)戊酸,6-苯基-2-丙基己酸,5-苯氧基-2-丙基戊酸,2-环己基甲基戊酸,2-(2-环己基乙基)戊酸,5-环己基-2-丙基戊酸,2-(2-乙氧基乙基)戊酸,2-(2-甲氧基乙基)戊酸,5-甲氧基-2-丙基戊酸,5-乙氧基-2-丙基戊酸,6-甲氧基-2-丙基己酸,2-苯基戊酸,2-苯氧基戊酸,2-环戊基戊酸,2-环己基戊酸,2-戊硫基戊酸,2-丙基-4-戊烯酸,2-丙基-7-辛烯酸,2-丙氧基戊酸,2-乙氧基戊酸,2-丁氧基戊酸,2-戊氧基戊酸,2-己氧基戊酸,2-丙基-2-戊烯酸。
本发明式(I)化合物制备方法如下:
(i)将式(II)化合物:
其中R1a为有1个碳原子被1或2个氟原子取代的C1-10烷基,而R2a为C1-4烷氧基;
或式(V)化合物:
其中R1d为有1个碳原子被3个氟原子取代的C1-10烷基,而R2a如上述;
或式(VIII)化合物氢化:
其中R1f为有1个碳原子被3个氟原子取代的C1-10烷基,而R2a如上述,
(ii)在碱性条件下将式(I-a)化合物的酯水解:
其中所有代号如上述,
(iii)将式(I-b)的酰氯化合物:
其中R1如上述;
(iii-1)与式(A)化合物反应:
HNR3R4 (A)
其中R3和R4如上述或
(iii-1)与式(H)化合物反应:
R2b-OH (H)
其中R2b为被1个苯基取代的C1-4烷基。
式(I)中NR3R4为含未酯化羧基的氨基酸残基的化合物制备方法是将反应(iii-1)所得式(I-c)中NR3R4为其羧基被苯甲基酯化的氨基酸的化合物氢化:
其中所有代号如上述。
式(II),(V),(VIII),(I-a)和(I-b)化合物可按反应式(A-1)和(A-2)所示得到。
反应式:(A-1)
反应式:(A-2)
上述式中R1b为有1个碳原子被1个酮基取代的C1-10烷基,R1c为有1个碳原子被1个羟基取代的C1-10烷基,R1e为有1个碳原子被1个羟基或3个氟原子取代的C1-10烷基,X为甲磺酸根,甲苯磺酸根或卤原子,而其它代号如上述。 DAST为二乙基氨基三氟化硫,LDA为二异丙基氨化锂,DBU为1,8-二氮杂双环[5.4.0]十一碳-7-烯。
反应(i)的氢化是已知的,例如可在有机溶剂[四氢呋喃(THF),二噁烷,乙醚,乙酸乙酯,甲醇,乙醇等]中用催化剂(钯/炭,钯,羟基钯,乙酸钯,钯黑,铂黑,镍,Ranney镍等)于常压或高压氢气下0-80℃进行。
反应(ii)中碱性条件下酯的水解是已知的,例如可在水可混的有机溶剂(THF,二噁烷,乙醇,甲醇,二甲氧基乙烷或这些溶剂中两种或多种的混合物等)中用碱水溶液(氢氧化钾,氢氧化钠等)于-10至100℃下进行。
反应(iii-1)的酰胺化反应已知,例如可用草酰氯进行后将所得化合物与式NR3R4中R3和R4如上述的胺在惰性有机溶剂(THF,二氯甲烷,甲苯,乙醚等)中于适宜碱(三乙胺等)存在或不存在下0-40℃反应。
氢化为同于上述的方法。
反应(iii-2)已知,例如用草酰氯进行后将所得化合物与式R2b-OH中R2b如上述的醇在惰性有机溶剂(THF,二氯甲烷,甲苯,乙醚等)中在适宜碱(三乙胺等)存在或不存在下0-40℃反应。
本发明式(X)化合物制备方法如下:
(i)将式(XI)化合物:
其中R7a为F-(CH2)m-,m为4-6,R6a为C1-4烷氧基,而n如上述;
或式(XIII)化合物氢化:
其中R7c为F3C-CH2-,被1或2个氯原子取代的C2-10烷基或被1或2个C1-4烷基,C3-7环烷基,苯基或苯氧基取代的C1-5烷基,而R6a如上述,
(ii)将式(XVI)化合物氢化:
其中R8a为C3-10烷基,而其它代号如上述,
(iii)将式(XVIII)化合物
其中所有代号如上述,与式(D)化合物反应:
R8b-Br (D)
其中R8b为C3-10烯基,或与式(E)化合物反应:
(R8c-S)2 (E)
其中R8c为C2-10烷基,
(iv)将式(XIX)化合物:
其中所有代号如上述,与式(F)化合物反应:
R8d-I (F)
其中R8d为C2-10烷基,
(v)将式(XX)化合物:
其中R8e为苯基,苯氧基或C3-7环烷基,R6a如上述,与式(G)化合物反应:
其中n如上述;
(vi)将式(XXI)化合物进行消去反应:
其中R8f为C2-9烷基,X为甲磺酸根,甲苯磺酸根或卤原子,而R6a和n如上述,
(vii)将式(X-a)化合物:
其中所有代号如上述,与四氯化碳反应,
(viii)将式(X-d)化合物进行还原反应和氧化反应:
其中所有代号如上述,
(ix)在碱性条件下将式(X-a)化合物的酯水解:
其中所有代号如上述,
(x)将式(X-b)的酰氯化合物:
其中所有代号如上述,
(x-1)与式(B)化合物反应:
HNR9R10 (B)
其中R9和R10如上述或
(x-2)与式(J)化合物反应:
R6b-OH (J)
其中R6b为被1个苯基取代的C1-4烷基。
式(X)中NR9R10为含未酯化羧基的氨基酸残基的化合物制备方法是将反应(x-1)所得式(X-c)中NR9R10为其羧基被苯甲基酯化的氨基酸的化合物氢化:
其中所有代号如上述。
式(XI),(XIII),(XVI),(XXI),(X-a),(X-b)和(X-d)化合物可按反应(B-1),(B-2)和(B-3)所示得到。
反应式:(B-1)
反应式:(B-2)
反应式:(B-3)
反应式中R7b为HO-(CH2)n-,n如上述,R7d为HO-(CH2)n-,n如上述,或F3C-CH2-或被1或2个氯原子取代的C2-10烷基或被1或2个C1-4烷氧基,C3-7环烷基,苯基或苯氧基取代的C1-5烷基,而其它代号如上述。DAST和LDA如上述,LAH为氢化锂铝,PDC为重铬酸吡啶鎓。
在本说明书所示每一反应中产物可按常规方法提纯,例如可通过常压或低压蒸馏,高效液相层析,薄层层析或硅胶或硅酸镁柱层析,洗涤或重结晶进行。可在每一反应后或在一系列反应后进行提纯。
本发明中原料和试剂本身已知或可按已知方法得到。
例如,式(VII)化合物中下式化合物已市售:
式(XV)化合物中下式化合物已市售:
式(XX)化合物中下式化合物也已市售:
式(VI)化合物中下式化合物可按已知方法得到:
例如可用已市售的下式化合物和已市售的三苯膦得到:
2-丙基戊酸及其无毒盐制备方法已见于US4127604的说明书。
本发明式(I)和(X)化合物及其无毒盐和酸加成盐可用于改进动物,包括人类且尤其是人类的大脑机能,因为这些化合物具有改进星形细胞机能的活性并且其毒性很低。目标病症具体例子如下:神经变性疾病(如Alzheimer病,肌萎缩性脊髓侧索硬化,进行性核上麻痹,橄榄体脑桥小脑萎缩),中风或外伤引起的神经元机能障碍[如Demyelinative病(多发性硬化等),脑瘤(星形细胞瘤等),感染(脑膜炎,脑脓肿,Creutzfeldt-Jakob病,AIDS病性痴呆等)]。
例如在标准的实验室试验中证实了以下效果。
试验1:改进星形细胞机能的效果
制备星形细胞培养物:去除脑膜后将新生鼠(1天龄)的分离大脑放在霜盖玻璃载玻片上并切碎。试样用胰蛋白酶(0.25%)和DNase I(0.02%)蒸煮后悬浮在10%FCS-DMEM中并进行离心分离。再悬浮在10%FCS-DMEM后将悬浮液分散在培养皿中并于37℃下5%CO2气氛中培养。在培养后24小时进行搅拌/洗涤后从培养皿中去除未粘连细胞。应注意,粘连细胞群体由95%以上的GFAP阳性细胞构成。
GFAP含量和GABAA受体反应:提高星形细胞机能的效果用以下参数评价:因GFAP含量增加带来的抑制和GABAA受体反应消失方面的抑制。因此,在1DIV加入丙戊酸钠(Sigma Chem.CO.,USA)后于7DIV进行全细胞模式电压夹方法以测定GABA(3×10-5M)诱发的Cl-电流。以Cl-电流作为GABA反应指数。此外,于11DIV按ELISA方法确定GFAP含量。
结果列于表1,其中GFAP含量以对照组的比率表示。
表1:改进星形细胞机能的效果
化合物 | 浓度(mM) | GFAP含量增加的比例(%) | GABAA受体反应(pA;平均±S.E.) |
对照 | 100.0 | 90±43 | |
VPA* | 0.31.03.0 | 30.636.344.3 | 254±106432±981301±156 |
*VPA:丙戊酸钠
从表1中可以看出,丙戊酸钠已使GABAA受体反应降低发生逆转并且GFAP含量(活性星形细胞指数)明显受到抑制。
基于这些发现可以看出,丙戊酸钠显示出有效改进星形细胞机能的效果。
试验2:抗活性星形细胞的GABAA受体反应再生效果
同于试验1制备和培养星形细胞。在14DIV,将活性星形细胞进行系列继代移植(105个细胞/培养皿)。将这样粘连的活性星形细胞洗涤后转入含本发明开发的有效化合物的培养基中。系列继代移植后14DIV按试验1说明的方法试验GABAA受体反应。
结果列于表2和3。
表2
Ex.No. | 浓度(mM) | GABAA受体反应(pA;平均±S.E.) |
对照 | 8±6 | |
2 | 0.31.0 | 193±103628±227 |
2(2) | 0.10.3 | 114±81527±201 |
2(5) | 3.0 | 326±148 |
2(6) | 0.33.0 | 184.0±118.1528.0±160.2 |
2(8) | 1.03.0 | 470.6±124.9808.6±325.4 |
2(9) | 0.3 | 236.4±85.5 |
2(10) | 0.3 | 800.0±415.6 |
2(12) | 1.03.0 | 672±2421109±227 |
表3
Ex.No. | 浓度(mM) | GABAA受体反应(pA;平均±S.E.) |
对照 | 8±6 | |
VPA* | 0.31.03.0 | 37±26193±1411263±303 |
7 | 0.31.0 | 213.1±150.1661.7±306.3 |
7(1) | 0.3 | 260.0±47.3 |
7(2) | 0.3 | 730.0±226.4 |
7(4) | 0.3 | 163.0±60.4 |
7(8) | 1.0 | 59.0±20.6 |
7(9) | 0.33.0 | 512.1±233.1226.3±60.5 |
7(14) | 3.0 | 285.7±103.6 |
7(16) | 0.31.0 | 105±65417±140 |
7(17) | 0.3 | 259.0±83.7 |
7(18) | 1.0 | 658.6±440.7 |
7(26) | 3.0 | 344.7±342.5 |
7(28) | 3.0 | 122±44 |
表3(续)
Ex.No. | 浓度(mM) | GABAA受体反应(pA;平均±S.E.) |
7(30) | 0.31.0 | 233±90675±201 |
7(31) | 0.31.03.0 | 51±28565±278590±180 |
7(32) | 0.1 | 48±20 |
7(33) | 0.030.10.3 | 40±23237±691260±521 |
7(37) | 0.33.0 | 139±52595±190 |
9 | 3.0 | 467±187 |
11 | 0.31.03.0 | 35±15190±134281±174 |
13 | 3.0 | 171±55 |
2-PNA** | 0.030.10.3 | 85±41107±50380±124 |
*VPA:丙戊酸钠
**2-PNA:2-丙基壬酸
从表2和3中可以看出,每一活性成分均显示出明显的对GABAA受体反应损失的再生效果。这一发现表明,有关的试验化合物可有效地将活性星形细胞转化为星形细胞。
试验3:对共生神经元-星形细胞共同培养体系中细胞坏死的抑制效果
同于试验1制备的星形细胞培养14天。将先期从19天龄胎儿鼠大脑分离得到的神经元(3×104个细胞/井)加入培养的星形细胞(3×105个细胞/井)中并使其生长。在培养工艺期间,观察神经元存活率和神经元树突延伸/分支。应注意,初期将丙戊酸钠(3mM)和星形细胞同时加入神经元中,并且新制得的含本发明化合物(3mM)的类似培养基然后以3-4天间隔加入。
结果列于表4。
表4:对神经元坏死的抑制效果
化合物 | 存活率(22天) |
对照 | <10% |
VPA | 60-80% |
VPA:丙戊酸钠
对照组中几乎所有神经元都坏死,而并没有观察到树突生成。但是,在丙戊酸钠处理的培养物中观测到明显的神经元存活率和树突生成。
试验4:对试验性脑局部缺血的效果
建立试验性脑局部缺血模型:使戊巴比妥麻醉的鼠脊椎动脉两侧凝固,并且过7天进行分离。先期经手术露出的局部缺血鼠的两侧颈总动脉机械结扎20分钟。去除结扎后立即连续4天每天一次给鼠i.p.注射丙戊酸钠(300mg/kg)。在去除结扎后5-6天,监测条件回避试验中的移动情况。
条件回避试验中的移动情况:使用暗/亮箱中的梯级模型。让放在带有关闭连接门的格栅底板箱的暗区中的动物熟悉环境1分钟。然后将门开10秒。经开启的门上到亮区中的鼠在条件回避试验中被认为显阳性。在该试验中被认为显阴性的动物放回暗区并让门关闭10秒,然后让其足部接受50秒2mA电击。经电击还未移动到箱的亮区的那些鼠从试验中去除。上述程序以30分钟间隔每天重复5次试验。2天内总共进行10次试验。
所得数据显示在图1中。与局部缺血的对照组(2.8±0.8)相比,由正常和假操作组记下的频率分别为6.1±0.7和4.8±0.8。但是,在丙戊酸钠处理组中则记录下5.3±0.8的数据,这表明由局部缺血脑的再循环诱发的学习条件回避反应中的移动障碍可通过本发明化合物得到改善。
本发明中每一活性成分及其无毒盐和酸加成盐的毒性很低。例如,丙戊酸钠用于鼠口服的急性毒性(LD50)为1700mg/kg(MerckIndex,11,pp 1559)。因此,可预期本发明中每一活性成分均可安全地作药用。
本发明式(I)和(X)化合物及其无毒盐和酸加成盐可用于改善大脑机能,因为这些化合物具有改善星形细胞机能的活性。
例如,这些化合物预期可用于防治神经变性疾病(如Alzheimer病,肌萎缩性脊髓侧索硬化,进行性核上麻痹,橄榄体脑桥小脑萎缩),中风或外伤引起的神经元机能障碍,Demyelinative病(多发性硬化等),脑瘤(星形细胞瘤等),感染(脑膜炎,脑脓肿,Creutzfeldt-Jakob病,AIDS病性痴呆等)。
为达到上述目的,本发明中每一活性成分,其无毒盐和酸加成盐通常可全身或局部投用,一般是口服或胃肠外投用。
投用剂量根据年龄,体重,症状,期望达到的效果,投用途径和治疗时间等确定。就成人而言,口服剂量/人/剂一般1-1000mg,每天可分几次服用,而胃肠外用药(优选i.v.注射投用)剂量/人/剂一般为100μg-100mg,同样每天可分几次服用。
如上所述,用药剂量取决于各种条件,因此也可使用药剂量低于或高于上列范围。
本发明化合物服用时可制成口服固体组合物,液体组合物或其它组合物,胃肠外投用的注射液,搽剂或栓剂等。
口服固体组合物包括压片,丸,胶囊,可分散粉和粒剂。
这些组合物中,一或多种活性化合物与至少一种惰性稀释剂(如乳糖,甘露糖醇,葡萄糖,羟丙基纤维素,微晶纤维素,淀粉,聚乙烯基吡咯烷酮,硅铝酸镁等)混合。
这些组合物中还可按常规包括除惰性稀释剂以外的其它物质如润滑剂(如硬脂酸镁等),崩解剂(如甘醇酸纤维素钙等),稳定剂和溶解助剂(如谷氨酸等)。
片或丸必要时可用胃或肠溶物质(如糖,明胶,羟丙基纤维素或羟丙基甲基纤维素邻苯二酸盐等)包衣或进行两次以上包衣。而且,包衣还可包括可吸收材料如明胶胶囊内含物。
胶囊包括硬胶囊和软胶囊。
口服液态组合物包括药用乳液,溶液,糖浆和酏剂。在这些组合物中一或多种活性成分含于本领域常用惰性稀释剂(净化水,乙醇等)中。
除惰性稀释剂之外,这些组合物中还可包括佐药(如润湿剂,悬浮剂等),甜味剂,调味剂,香料和防腐剂。
其它口服组合物包括可按已知方法得到并且包括一或多种活性化合物的喷雾组合物。这些喷雾组合物中除惰性稀释剂而外还可包括其它物质如稳定剂(硫酸钠等),等渗缓冲系(氯化钠,柠檬酸钠,柠檬酸等)。为制成这些喷雾组合物,可采用例如US2868691或3095355(其全部分开内容供本文参考)中所述方法。
胃肠外投用的注射液包括无菌水或非水溶液,悬浮液或乳液。水溶液,悬浮液包括注射用蒸馏水和生理盐水。非水溶液,悬浮液包括丙二醇,聚乙二醇,植物油如橄榄油,醇如乙醇,POLYSORBATE80(注册商标)等。
注射液还可包括惰性稀释剂以外的其它物质如防腐剂,润湿剂,乳化剂,分散剂,稳定剂(人血清白蛋白,乳糖),助剂如溶解助剂(精氨酸,谷氨酸,天冬氨酸,聚乙烯基吡咯烷酮等)。
可通过例如持菌过滤器过滤,组合物中加灭菌剂或辐照等办法使这些注射液灭菌。这些注射液也可经冻干法制成无菌固体组合物并在投用前夕将其溶子注射用灭菌水或某些其它灭菌稀释剂中。
其它胃肠外投用组合物包括外用液体,皮肤搽剂,软膏,直肠给药栓剂和阴道给药栓剂,这些组合物可包括一或多种活性成分并可按本身已知的方法得到。
以下参考例和实施例详述本发明,但并不限制本发明。
括号中的溶剂表示展开或洗脱溶剂,所用溶剂比例为层析分离时的体积比。
除另有说明而外,“NMR”在甲醇-d(CD3OD)液中测定,而“IR”用液膜法测定。
参考例1
氩气下将(1-甲氧羰基-1-亚丁基)三苯基正磷(5.52g)加入5-羟基戊醛(1.00g)的苯(15ml)溶液中,混合物80℃搅拌15小时。反应混合物减压浓缩后剩余物经硅胶柱层析(己烷∶乙酸乙酯=3∶1)提纯而得题示化合物(1.17g),其物理数据如下。
TLC:Rf0.42(己烷∶乙酸乙酯=2∶1)
参考例2
氩气下向参考例1所得化合物(389mg)的四氢呋喃(THF)(5ml)溶液中依次加入二甲亚砜(5ml),三乙胺(3ml)和三氧化硫吡啶配合物(819mg)。反应液用乙醚稀释,依次用饱和氯化铵水溶液,水和饱和氯化钠水溶液洗涤后用无水硫酸镁干燥并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=7∶1)提纯而得题示化合物(268mg),其物理数据如下。
TLC:Rf0.55(己烷∶乙酸乙酯=3∶1)
参考例3
氩气下-78℃将参考例2所得化合物(268mg)的无水二氯甲烷(2ml)溶液滴入二乙基氨基三氟化硫(DAST)(393μl)的无水二氯甲烷(2ml)溶液中。混合物0℃搅拌2.5小时后用乙醚稀释,依次用水和饱和氯化钠水溶液洗涤后用无水硫酸镁干燥并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=20∶1)提纯而得题示化合物(275mg),其物理数据如下。
TLC:Rf0.49(己烷∶乙酸乙酯=10∶1)
参考例5
THF(6ml)冷至-78℃后向其中加入二异丙基酰胺(LDA)(2.94ml)并搅拌。再向混合物中加入4,4,4-三氟丁酸乙酯(1.00g)并于-78℃搅拌20分钟。然后向混合物中滴入丙醛(0.47ml)并于-78℃搅拌15分钟。加2N盐酸使反应混合物酸化后用乙酸乙酯萃取。有机层依次用水和饱和氯化钠水溶液洗涤后用无水硫酸镁干燥并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=5∶1)提纯而得题示化合物(875mg),其物理数据如下。
TLC:Rf0.33(己烷∶乙酸乙酯=5∶1)
参考例6
将参考例5所得化合物(875mg)溶于二氯甲烷(10ml)和三乙胺(1ml)的混合物液中。混合物冷至0℃后滴入甲磺酰氯(0.446ml)并于0℃搅拌30分钟。再将反应混合物倒入水中并用乙醚萃取。有机层依次用水和饱和氯化钠水溶液洗涤后用无水硫酸镁干燥并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=10∶1)而得题示化合物(540mg),其物理数据如下。
TLC:Rf0.33(己烷∶乙酸乙酯=2∶1)
参考例7
向参考例6所得化合物(540mg)的苯(6ml)溶液中滴入1,8-二氮杂双环[5.4.0]十一碳-7-烯(DBU)(1ml)。混合物回流2小时后倒入水中并用乙醚萃取。有机层依次用2N盐酸,水和饱和氯化钠水溶液洗涤后用无水硫酸镁干燥并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=30∶1)提纯而得题示化合物(335mg),其物理数据如下。
TLC:Rf0.55(己烷∶乙酸乙酯=5∶1)
实施例1
氩气下向参考例3所得化合物(275mg)的乙醇(3ml)溶液中加入10%钯/炭(30mg)。混合物在氢气和室温下充分搅拌8小时后经Celite过滤并将滤液减压浓缩而得题示化合物,其物理数据如下。
TLC:Rf0.62(己烷∶乙酸乙酯=10∶1)
实施例2
向实施例1所得化合物的乙醇(8ml)溶液中加入5N氢氧化钠水溶液(2ml)。混合物70℃搅拌2小时后减压浓缩。剩余物中加2N盐酸酸化后用乙酸乙酯萃取。有机层依次用水和饱和氯化钠水溶液洗涤后用无水硫酸镁干燥并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=5∶1-2∶1)而得游离酸化合物(238mg)。向该化合物的乙醇(5ml)溶液中加入1N氢氧化钠水溶液(1.06ml)并将混合物减压浓缩而得题示化合物,其物理数据如下。
TLC:Rf0.21(己烷∶乙酸乙酯=5∶1)
IR:ν3392,2935,2871,1557,1456,1416,1318,1173,1123,1058cm-1;
NMR:δ5.87(1H,tt),2.22(1H,m),1.98-1.23(12H,m),0.94(3H,t)。
实施例2(1)-2(10)
可用相应的醛按照与参考例1→参考例2→参考例3→实施例1→实施例2或参考例1→参考例3→实施例1→实施例2或参考例1→实施例1→实施例2的反应相同的程序得到以下化合物。
实施例2(1)
TLC:Rf0.24(己烷∶乙酸乙酯=3∶1);
IR(KBr):ν3436,2963,2937,2875,1639,1558,1495,1412,1326,1195,1123,1048,964,583cm-1;
NMR:δ5.89(1H,tt),2.23(1H,m),1.2-2.0(8H,m),0.95(3H,t)。
实施例2(2)
TLC:Rf0.01(己烷∶乙酸乙酯=10∶1);
IR:ν3366,2934,2863,1557,1416,1124,1032cm-1;
NMR:δ5.87(1H,tt),2.23(1H,m),1.20-2.00(14H,m),0.94(3H,t)。
实施例2(3)
TLC:Rf0.64(己烷∶乙酸乙酯=1∶1);
IR(KBr):ν3401,2874,1564,1447,1417,1380,1320,1182,1121,1048,1005,835,755,559,427cm-1;
NMR:δ5.87(1H,tt),2.24(1H,m),1.20-2.00(10H,m),0.95(3H,t)。
实施例2(4)
TLC:Rf0.55(己烷∶乙酸乙酯=2∶1);
IR:ν3368,2932,2860,1556,1445,1418,1124,1039,859,727cm-1;
NMR:δ5.87(1H,tt),2.22(1H,m),1.20-2.00(16H,m),0.94(3H,t)。
实施例2(5)
TLC:Rf0.41(己烷∶乙酸乙酯=2∶1);
IR(KBr):ν3651,3436,2961,2936,2874,1640,1553,1458,1412,1322,1113,1021,935,563cm-1;
NMR:δ4.40(2H,dtd),2.21(1H,m),1.25-1.85(8H,m),0.91(3H,t)。
实施例2(6)
TLC:Rf0.61(己烷∶乙酸乙酯=1∶1)
IR(KBr):ν3402,2935,2873,1561,1459,1415,1321,1112,1037,750,560cm-1;
NMR:δ4.43(2H,td),2.23(1H,m),1.20-1.90(10H,m),0.95(3H,t)。
实施例2(7)
TLC:Rf0.43(己烷∶乙酸乙酯=2∶1);
IR:ν3436,2936,2862,1556,1467,1443,1418,1390,1337,1257,1211,1178,1145,1041,837,728,656,567cm-1;
NMR:δ2.33-1.94(3H,m),1.67-1.18(14H,m),0.90(3H,t)。
实施例2(8)
TLC:Rf0.36(己烷∶乙酸乙酯=2∶1);
IR(KBr):ν3401,2982,2937,1561,1466,1446,1418,1392,1360,1311,1257,1209,1153,1097,1041,1017,926,846,756,656,551,422cm-1;
NMR:δ2.30-1.90(3H,m),1.75-1.15(8H,m),0.91(3H,t)。
实施例2(9)
TLC:Rf0.49(己烷∶乙酸乙酯=2∶1);
IR(KBr):ν3431,2937,2863,1639,1554,1460,1443,1415,1390,1319,1257,1190,1146,1097,838,656cm-1;
NMR:δ2.35-1.95(3H,m),1.70-1.10(12H,m),0.90(3H,t)。
实施例2(10)
TLC:Rf0.36(己烷∶乙酸乙酯=3∶1);
IR(KBr):ν3436,2937,2876,1736,-1555,1459,1420,1390,1336,1256,1200,1148,1083,1026,839,656cm-1;
NMR:δ2.30-1.95(3H,m),1.74-146(10H,m),0.90(3H,t)。
实施例2(11)-2(12)
可用参考例7所得化合物或用与参考例5→参考例6→参考例7的反应相同的方法得到的相应化合物按照与实施例1→实施例2的反应相同的程序得到以下化合物。
实施例2(11)
TLC:Rf0.40(己烷∶乙酸乙酯=2∶1);
IR(KBr):ν3436,2965,2879,1572,1439,1416,1377,1328,1254,1158,1117,1083,995,957,866,830,743,660,625,592,515cm-1;
NMR:δ2.73-2.40(2H,m),2.25-1.94(1H,m),1.70-1.25(4H,m),0.92(3H,t)。
实施例2(12)
TLC:Rf0.22(己烷∶乙酸乙酯=3∶1);
IR(KBr):ν3431,2960,2876,1562,1460,1418,1389,1340,1306,1257,1227,1155,1099,1051,985,907,858,572cm-1;
NMR:δ2.30-1.90(3H,m),1.80-1.20(6H,m),0.92(3H,t)。
实施例3
室温下向实施例2(8)所得游离酸化合物(0.5g)溶液中加入草酰氯(1.85ml)。混合物室温搅拌2小时后减压浓缩而得酰氯。0℃下将该酰氯在乙醚(2ml)中的溶液滴入4-甲氧基苯胺(218mg)和三乙胺(1ml)的乙醚(10ml)溶液中。混合物再搅拌1小时后依次用2N盐酸,水和饱和氯化钠水溶液洗涤,用无水硫酸镁干燥后减压浓缩。剩余物经正己烷和乙酸乙酯的混合物(10∶1)重结晶而得题示化合物(412mg),其物理数据如下。
TLC:Rf0.43(己烷∶乙酸乙酯=2∶1)
IR(KBr):ν3449,3243,2951,2870,1655,1603,1546,1515,1459,1445,1417,1393,1364,1321,1286,1252,1212,1199,1182,1144,1131,1093,1036,832,741,656,558,529,430cm-1;
NMR(CDCl3+CD3OD):δ7.46(2H,d),6.86(2H,d),3.80(3H,s),2.38-1.95(3H,m),1.85(8H,m),0.92(3H,t)。
实施例3(1)-3(5)
用相应化合物代替实施例3中的4-甲氧基苯胺并按照与实施例3或实施例3→实施例1的反应相同的程序可得到以下化合物。
实施例3(1)
TLC:Rf0.63(己烷∶乙酸乙酯=2∶1
IR(KBr):ν3280,3090,2955,2875,1640,1553,1498,1459,1393,1357,1286,1255,1220,1206,1155,1136,1098,1045,1027,1004,836,743,693,658,580,539,491,426cm-1;
NMR:δ7.45-7.10(5H,m),5.90-5.60(1H,br),4.45(2H,d),2.20-1.85 3H,m),1.80-1.10(8H,m),0.90(3H,t)。
实施例3(2)
TLC:Rf0.38(氯仿∶甲醇=10∶1)
IR(KBr):ν3293,3253,3189,3133,2955,2875,1660,1603,1547,1484,1467,1413,1396,1329,1298,1261,1201,1147,1098,1053,1021,942,887,813,747,712,636cm-1;
NMR:δ8.56(1H,d),8.35(1H,d),8.21(1H,dd),7.61(1H,s),7.30(1H,dd),2.35-1.90(3H,m),1.90-1.20(8H,m),0.93(3H,t).
实施例3(3)
TLC:Rf0.20(氯仿∶甲醇=10∶1)
[α]D-25.39(c=1.01,EtOH)
IR(KBr):ν3293,3089,2940,2878,1719,1646,1547,1466,1397,1377,1360,1327,1287,1260,1222,1210,1132,1054,1025,946,837,659,592,422cm-1;
NMR:δ9.20-8.60(1H,br),6.40-6.00(1H,br),4.75-4.40(1H,br),2.30-1.10(11H,br),1.00-0.85(3H,br)。
实施例3(4)
TLC:Rf0.29(氯仿∶甲醇=10∶1)
IR(KBr):ν3302,2960,2876,2664,1694,1661,1591,1552,1451,1414,1359,1288,1257,1194,1148,1093,1050,1016,948,911,815,756,685,665,665,564cm-1;
NMR(CDCl3+CD3OD):δ8.07(1H,dd),7.98(1H,d),7.78(1H,dd),7.41(1H,t),2.42-1.90(3H,m),1.85-1.15(8H,m),0.93(3H,t).
实施例3(5)
TLC:Rf0.54(己烷∶乙酸乙酯=5∶1)
IR(KBr):ν3031,2960,2875,1733,1498,1456,1392,1256,1210,1148,748,700cm-1;
NMR(CDCl3):δ7.30-7.19(5H,m),4.32(2H,t),2.94(2H,t),2.40-2.25(1H,m),2.10-1.85(2H,m),1.80-1.10(8H,m),0.86(3H,t)。
参考例4
氩气下-78℃将参考例1所得化合物(400mg)的无水二氯甲烷(2ml)溶液中滴入DAST(316μl)的无水二氯甲烷(2ml)溶液中。混合物0℃搅拌1.5小时后用乙醚稀释,依次用水和饱和氯化钠水溶液洗涤并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=20∶1)提纯而得题示化合物(132mg),其物理数据如下。
TLC:Rf0.67(己烷∶乙酸乙酯=3∶1)
实施例4
氩气下向参考例4所得化合物(132mg)的乙醇(2ml)溶液中加入10%钯/炭(10mg)。混合物氢气中室温下充分搅拌2小时后经Celite过滤并用乙酸乙酯洗涤。有机层减压浓缩而得题示化合物,其物理数据如下。
TLC:Rf0.48(己烷∶乙酸乙酯=10∶1)
实施例5
氩气下0℃向二异丙胺(1.3ml)的无水THF(10ml)溶液中滴入1.6M正丁基锂的己烷(4.6ml)溶液。混合物搅拌30分钟后-78℃向其中滴入乙酸乙基苯基酯(1.00g)的THF(3ml)溶液。混合物再搅拌40分钟后向其中滴入1-碘丙烷(1.24g)的THF(2ml)溶液和六甲基磷酰胺(2ml)的混合物。混合物再搅拌3小时后用乙醚稀释,依次用饱和氯化铵水溶液,水和饱和氯化钠水溶液洗涤,用无水硫酸镁干燥后减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=40∶1)提纯而得题示化合物(788mg),其物理数据如下。
TLC:Rf0.43(己烷∶乙酸乙酯=20∶1)
实施例6
氩气下0℃向2-羟基戊酸甲酯(300mg)的二甲基甲酰胺(DMF)(3ml)溶液中加入氢化钠(109mg)。混合物室温下搅拌30分钟后向其中滴入1-碘丙烷(266μl)。混合物再搅拌8小时后用乙醚稀释,依次用水和饱和氯化钠水溶液洗涤,用无水硫酸镁干燥后减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=30∶1)提纯而得题示化合物(91mg),其物理数据如下。
TLC:Rf0.7.5(己烷∶乙酸乙酯=3∶1)
实施例7
向实施例4所得化合物的乙醇(2ml)溶液中加入5N氢氧化钠溶液(0.5ml)。混合物60℃下搅拌2小时后减压浓缩。剩余物经2N盐酸酸化后用乙酸乙酯萃取。有机层依次用水和饱和氯化钠水溶液洗涤,用无水硫酸镁干燥并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=4∶1-2∶1)提纯而得游离酸化合物(112mg)。向上述化合物的乙醇(2ml)溶液中加入1N氢氧化钠水溶液(534μl)。混合物减压浓缩而得题示化合物,其物理数据如下。
TLC:Rf0.12(己烷∶乙酸乙酯=4∶1)
IR:ν3368,2934,2862,1557,1455,1417,1318,1044,749cm-1;
NMR:δ4.43(2H,td),2.23(1H,m),1.85-1.20(12H,m),0.94(3H,t)。
实施例7(1)-7(22)
用相应醛按照与参考例1→参考例4→实施例4→实施例7或参考例1→实施例4→实施例7的反应相同的程序可得到以下化合物。
实施例7(1)
TLC:Rf0.38(己烷∶乙酸乙酯=3∶1)
NMR:δ4.43(2H,td),2.23(1H,m),1.22-1.89(14H,m),0.95(3H,t)。
实施例7(2)
TLC:Rf0.74(己烷∶乙酸乙酯=2∶1)
NMR:δ4.43(2H,td),2.22(1H,m),1.20-1.85(16H,m),0.94(3H,t)。
实施例7(3)
TLC:Rf0.33(己烷∶乙酸乙酯=4∶1)
NMR:δ2.32(1H,m),1.97-1.80(1H,br),1.77-1.03(14H,m),1.00-0.70(5H,m)。
实施例7(4)
TLC:Rf0.29(己烷∶乙酸乙酯=4∶1)
NMR:δ2.13(1H,m),1.80-1.05(17H,m),1.00-0.73(5H,m)。
实施例7(5)
TLC:Rf0.35(己烷∶乙酸乙酯=4∶1)
NMR:δ2.17(1H,m),1.78-1.05(19H,m),1.00-0.70(5H,m)。
实施例7(6)
TLC:Rf0.32(己烷∶乙酸乙酯=3∶1)
NMR:δ7.30-7.05(5H,m),3.00-2.85(1H,m),2.70-2.40(2H,m),1.70-1.10(4H,m),0.87(3H,t)。
实施例7(7)
TLC:Rf0.30(己烷∶乙酸乙酯=4∶1)
NMR:δ7.30-7.00(5H,m),2.60(2H,t),2.21(1H,m),1.75-1.15(8H,m),0.89(3H,t)。
实施例7(8)
TLC:Rf0.31(己烷∶乙酸乙酯=3∶1)
NMR:δ7.35-7.00(5H,m),2.58(2H,t),2.30-2.05(1H,m),1.80-1.10(10H,m),0.89(3H,t)。
实施例7(9)
TLC:Rf0.21(己烷∶乙酸乙酯=5∶1)
NMR:δ7.20(2H,m),6.92(3H,m),3.99(2H,m),2.27(1H,m),1.31-1.89(8H,m),0.95(3H,m)。
实施例7(10)
TLC:Rf0.26(己烷∶乙酸乙酯=3∶1)
NMR:δ3.55-3.35(4H,m),2.36-2.15(1H,m),1.95-1.23(6H,m),1.16(3H,t),0.91(3H,t)。
实施例7(11)
TLC:Rf0.16(己烷∶乙酸乙酯=2∶1)
NMR:δ3.40(2H,t),3.29(3H,s),2.35-2.15(1H,br),1.92-1.20(6H,m),0.91(3H,t)。
实施例7(12)
TLC:Rf0.32(己烷∶乙酸乙酯=1∶1)
NMR:δ3.50-3.20(5H,m),2.30-2.05(1H,br),1.75-1.15(8H,m),0.90(3H,t)。
实施例7(13)
TLC:Rf0.41(己烷∶乙酸乙酯=1∶1)
NMR:δ3.55-3.38(4H,m),2.30-2.08(1H,m),1.70-1.20(8H,m),1.16(3H,t),0.90(3H,t)。
实施例7(14)
TLC:Rf0.32(己烷∶乙酸乙酯=1∶1)
NMR:δ3.45-3.30(2H,m),3.30(3H,s),2.30-2.05(1H,m),1.70-1.15(10H,m),0.95-0.80(3H,br)。
实施例7(15)
TLC:Rf0.22(己烷∶乙酸乙酯=10∶1)
NMR:δ2.32(1H,m),1.02-1.74(7H,m),0.92(9H,m)。
实施例7(16)
TLC:Rf0.38(己烷∶乙酸乙酯=4∶1)
NMR:δ2.15(1H,m),1.70-1.10(9H,m),1.00-0.75(9H,m)。
实施例7(17)
TLC:Rf0.34(己烷∶乙酸乙酯=3∶1)
NMR:δ2.25-2.08(1H,m),1.65-1.05(13H,m),0.90(3H,t),0.87(6H,d)。
实施例7(18)
TLC:Rf0.35(己烷∶乙酸乙酯=3∶1)
NMR:δ2.30-2.05(1H,m),1.67-1.07(11H,m),0.90(3H,t),0.87(6H,d)。
实施例7(19)
TLC:Rf0.34(己烷∶乙酸乙酯=3∶1)
NMR:δ2.22-2.05(1H,m),1.65-1.05(13H,m),0.88(3H,t),0.85(6H,t)。
实施例7(20)
TLC:Rf0.29(己烷∶乙酸乙酯=5∶1)
NMR:δ2.20-2.00(1H,br),1.65-1.10(8H,m),0.95-0.80(12H,m)。
实施例7(21)
TLC:Rf0.53(己烷∶乙酸乙酯=3∶1)
NMR:δ2.24(1H,m),1.13-1.70(10H,m),0.92(12H,m)。
实施例7(22)
TLC:Rf0.47(氯仿∶甲醇=10∶1)
NMR:δ3.53(2H,t),2.28-2.10(1H,m),2.85-1.20(12H,m),0.90(3H,t)。
实施例7(23)-7(33)
按照实施例7相同的程序用实施例5所得化合物或用相应乙酸酯代替实施例5中的乙酸乙基苯基酯按同于实施例5的方法得到的化合物或用相应戊酸酯代替乙酸乙基苯基酯并用相应化合物代替实施例5中的1-碘丙烷按同于实施例5的方法得到的化合物或者按照与实施例5→实施例4→实施例7的反应相同的程序用相应羧酸酯代替乙酸乙基苯基酯并用3-溴-1-丙烯代替1-碘丙烷可得到以下化合物。
实施例7(23)
TLC:Rf0.27(己烷∶乙酸乙酯=1∶1)
NMR:δ7.40(2H,m),7.20(3H,m),3.45(1H,m),2.00(1H,m),1.65(1H,m),1.30(2H,m),0.95(3H,t)。
实施例7(24)
TLC:Rf0.12(己烷∶乙酸乙酯=1∶1)
NMR:δ7.20(2H,m),6.90(3H,m),4.35(1H,m),1.90(2H,m),1.55(2H,m),0.95(3H,m)。
实施例7(25)
TLC:Rf0.24(己烷∶乙酸乙酯=10∶1)
NMR:δ1.02-2.05(14H,m),0.92(3H,t)。
实施例7(26)
TLC:Rf0.5(己烷∶乙酸乙酯=3∶1)
NMR:δ1.00-2.04(16H,m),0.94(3H,t)。
实施例7(27)
TLC:Rf0.56(己烷∶乙酸乙酯=1∶1)
NMR:δ3.24(1H,dd),2.63(1H,t),2.60(1H,t),1.30-1.90(10H,m),0,97(3H,t),0.94(3H,t)。
实施例7(28)
TLC:Rf0.11(己烷∶乙酸乙酯=10∶1)
NMR:δ5.85(1H,m),4.98(2H,m),2.00-2.50(3H,m),1.20-1.70(4H,m),0.93(3H,m)。
实施例7(29)
TLC:Rf0.29(己烷∶乙酸乙酯=3∶1)
NMR:δ5.80(1H,m),5.03-4.90(2H,m),2.27-1.95(3H,m),1.65-1.15(10H,m),0.89(3H,t)。
实施例7(30)
TLC:Rf0.31(己烷∶乙酸乙酯=5∶1)
NMR:δ2.19(1H,m),1.65-1.12(12H,m),0.90(3H,t),0.89(3H,t)。
实施例7(31)
TLC:Rf0.37(己烷∶乙酸乙酯=5∶1)
NMR:δ2.30-2.07(1H,m),1.65-1.10(10H,m),0.95-0.75(6H,m)。
实施例7(32)
TLC:Rf0.31(己烷∶乙酸乙酯=5∶1)
NMR:δ2.27-2.08(1H,m),1.65-1.15(18H,m),0.95-0.85(6H,m)。
实施例7(33)
TLC:Rf0.50(己烷∶乙酸乙酯=3∶1)
NMR:δ2.25(1H,m),1.20-1.70(14H,m),0.93(6H,m)。
实施例7(34)-7(38)
按照与实施例7相同的程序用实施例6所得化合物或用相应碘代烷代替实施例6中的1-碘丙烷按同于实施例6的方法得到的化合物可得到以下化合物。
实施例7(34)
TLC:Rf0.11(己烷∶乙酸乙酯=1∶1)
NMR:δ3.45-3.65(2H,m),3.71(1H,td),1.30-1.70(6H,m),0.91(6H,t)。
实施例7(35)
TLC:Rf0.29(己烷∶乙酸乙酯=10∶1)
NMR:δ3.64(2H,m),3.35(1H,q),1.72-1.25(4H,m),1.19(3H,t),0.92(3H,t)。
实施例7(36)
TLC:Rf0.5(乙酸乙酯)
NMR:δ3.66(2H,m),3.28(1H,m),1.32-1.74(8H,m),0.96(6H,t)。
实施例7(37)
TLC:Rf0.5(乙酸乙酯)
NMR:δ3.66(2H,m),3.26(1H,m),1.30-1.76(10H,m),0.96(6H,t)。
实施例7(38)
TLC:Rf0.12(己烷∶乙酸乙酯=1∶1)
NMR:δ3.67(2H,m),3.30-3.15(1H,m),1.72-1.10(12H,m),0.98-0.83(6H,m)。
实施例8
室温下向2-丙基辛酸(500mg)的无水苯(5ml)溶液中加入草酰氯(350ml)。混合物50℃搅拌30分钟后减压浓缩而得酰氯。0℃将该酰氯的THF(3ml)溶液滴入50%二甲基胺(3ml)溶液中。混合物再搅拌1小时后用乙醚稀释,依次用2N盐酸,水和饱和氯化钠水溶液洗涤,用无水硫酸镁干燥后减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=2∶1)提纯而得题示化合物(412mg),其物理数据如下。
TLC:Rf0.43(己烷∶乙酸乙酯=2∶1)
IR:ν2957,2928,2857,1661,1646,1466,1414,1397,1337,1262,1155,1111cm-1;
NMR(CDCl3):δ3.04(3H,s),2.96(3H,s),2.65(1H,m),1.10-1.85(14H,m),0.87(3H,t),0.86(3H,t)。
实施例8(1)-8(6)
按照与实施例8相同的程序用相应的羧酸和相应的胺可得到以下化合物。
实施例8(1)
TLC:Rf0.19(己烷∶乙酸乙酯=2∶1)
NMR:δ5.70-5.30(1H,br),2.81(3H,d),2.02(1H,m),1.80-1.10(8H,m),0.89(6H,t)。
实施例8(2)
TLC:Rf0.30(己烷∶乙酸乙酯=2∶1)
NMR:δ3.06(3H,s);2.97(3H,s),2.68-(1H,m),1.75-1.45(2H,m),1.45-1.10(6H,m),0.89(6H,t)。
实施例8(3)
TLC:Rf0.22(己烷∶乙酸乙酯=2∶1)
NMR(CDCl3):δ5.64(1H,brs),5.43(1H,brs),2.11(1H,m),1.10-1.80(14H,m),0.90(3H,t),0.86(3H,t)。
实施例8(4)
TLC:Rf0.64(己烷∶乙酸乙酯=2∶1)
NMR(CDCl3):δ5.22(1H,brd),4.10(1H,m),1.91(1H,m),1.18-1.75(14H,m),1.14(6H,d),0.88(3H,t),0.86(3H,t)。
实施例8(5)
TLC:Rf0.41(己烷∶乙酸乙酯=4∶1)
NMR:δ3.59(2H,t),3.49(2H,t),2.73-2.58(1H,m),1.75-1.45(9H,m),1.45-1.10(11H,m),0.93-0.81(6H,m)。
实施例8(6)
TLC:Rf0.20(己烷∶乙酸乙酯=4∶1)
NMR:δ3.67(4H,s),3.68-3.60(2H,m),3.59-3.49(2H,m),2.69-2.52(1H,m),1.74-1.51(2H,m),1.50-1.08(12H,m),0.93-0.80(6H,m)。
实施例9
氩气下0℃向二异丙胺(1.6ml)的无水THF(10ml)溶液中滴入1.6M正丁基锂的己烷(5.9ml)溶液。混合物搅拌30分钟后-78℃向其中滴入2-丙基戊酸甲酯(1.00g)的THF(3ml)溶液。混合物搅拌15分钟后再搅拌20分钟。-78℃再向反应混合物中加入四氯化碳(1.17g)的THF(2ml)溶液。混合物室温再搅拌80分钟后向其中加入1N盐酸。所得混合物用乙醚稀释,依次用水和饱和氯化钠水溶液洗涤,用无水硫酸镁干燥后减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=40∶1)提纯而得题示化合物,其物理数据如下。
TLC:Rf0.45(己烷∶乙酸乙酯=10∶1)
NMR(CDCl3):δ3.76(3H,s),2.1-1.8(4H,m),1.6-1.1(4H,m),0.92(6H,t)。
实施例10
氩气下0℃向实施例9所得化合物(600mg)的无水乙醚(10ml)溶液中加入氢化锂铝(119mg)。混合物搅拌30分钟后用乙醚稀释剂,用饱和氯化钠水溶液洗涤,用无水硫酸镁干燥并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=10∶1)提纯而得2-氯-2-丙基戊醇。氩气下向上述化合物的无水二氯甲烷(14ml)溶液中加入4A分子筛(1.5g)和重铬酸吡啶鎓(1.29g)。混合物室温下搅拌3小时后用乙醚稀释并用硅胶过滤。滤液减压浓缩后剩余物经硅胶柱层析(己烷∶乙酸乙酯=40∶1)提纯。向所得醛化合物的叔丁醇(3ml)溶液中加入2-甲基-2-丁烯(0.2ml)。然后将氯化钠(248mg)和磷酸一钠二水合物(215mg)的水(1ml)溶液加入混合物中。混合物再于室温下搅拌30分钟后用乙酸乙酯稀释,依次用水和饱和氯化钠水溶液洗涤,用无水硫酸镁干燥后减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=1∶1)提纯而得游离酸化合物(150mg)。向上述化合物的乙醇(3ml)溶液中加入1N氢氧化钠水溶液(800ml)。混合物减压浓缩而得题示化合物(134mg),其物理数据如下。
TLC:Rf0.11(己烷∶乙酸乙酯=10∶1)
IR(KBr):ν3449,2963,2876,1600,1433,1402,1132,763,665cm-1;
NMR:δ1.28-2.14(8H,m),0.95(6H,t)。
实施例11
市售(±)-乙基己酸(5g)和奎宁(5.6g)加热溶于50%含水丙酮中。混合物放置过夜后过滤出沉淀的晶体。该粗晶体加压干燥后用含水丙酮(6次)重结晶。再将所得晶体溶于稀盐酸中并用乙醚萃取。有机层依次用水和饱和氯化钠水溶液洗涤后干燥和减压浓缩而得题示化合物(190mg),其物理数据如下。
[α]D-8.7°(c=2.59,CHCl3);
IR:ν2964,2876,1708,1461,1290,1231cm-1。
参考例8
氩气下将二异丙基氨化锂的庚烷-四氢呋喃-乙基苯溶液(2M5ml)加入THF(5ml)中。混合物冷至-70℃后向溶液中加入戊酸甲酯(1.33ml)的THF(3ml)溶液。所得混合物再于-70℃下搅拌30分钟后向反应混合物中滴入丙醛(0.72ml)的THF(3ml)溶液。混合物再于-70℃下搅拌15分钟后向反应混合物中加入饱和氯化铵水溶液。混合物用乙酸乙酯萃取后有机层依次用水和饱和氯化钠水溶液洗涤,干燥后减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=9∶1)提纯而得羟基化合物(752mg)。氩气下将三乙胺(0.57ml)加入上述化合物(550mg)的二氯甲烷(10ml)溶液中。混合物冷至-20℃后向该溶液中滴入甲磺酰氯溶液(0.29ml)。混合物-20℃至-10℃下搅拌30分钟后倒入冰水中并用乙酸乙酯萃取。萃取液用饱和氯化钠水溶液洗涤后干燥并减压浓缩而得题示化合物,该化合物可不经提纯而用于下一反应步骤。
实施例12
向参考例8所得化合物的苯(10ml)溶液中加入DBU(0.56ml)并于室温下搅拌16小时。将反应液倒入冷的1N盐酸中并用乙酸乙酯萃取。该萃取液依次用水和饱和氯化钠水溶液洗涤后干燥并减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=20∶1)而得题示化合物(164mg)和EZ混合物(114mg)。
实施例13
向实施例12所得E化合物(160mg)中加入1N氢氧化钠水溶液。混合物室温下搅拌1小时和50℃搅拌1小时后室温再搅拌12小时。反应液有乙醚稀释后加水。溶液分离后水层用1N盐酸酸化并用乙酸乙酯萃取。该萃取液依次用水和饱和氯化钠水溶液洗涤,干燥后减压浓缩。剩余物经硅胶柱层析(己烷∶乙酸乙酯=10∶1-2∶1)提纯而得游离酸化合物(117mg)。向上述化合物的二噁烷溶液中加入1N氢氧化钠水溶液。混合物冻干而得题示化合物,其物理数据如下。
TLC:Rf0.22(己烷∶乙酸乙酯=3∶1)
IR(KBr):ν3436,2962,2933,2872,1649,1558,1461,1411,1111 849,798cm-1。
配方例1:制备片剂
以下化合物按常规方法混合后冲压成每片含100mg活性成分的100片。
5,5,5-三氟-2-丙基戊酸钠 10g
甘醇酸纤维素钙(崩解剂) 200mg
硬脂酸镁(润滑剂) 100mg
微晶纤维素 9.7g。
配方例2:制备片剂
以下化合物按常规方法混合后冲压成每片含100mg活性成分的100片。
2-丙基戊酸钠 10g
甘醇酸纤维素钠(崩解剂) 200mg
硬脂酸镁(润滑剂) 100mg
微晶纤维素 9.7g
图1示出了丙戊酸钠对脑局部缺血的效果。
Claims (9)
1.式(X)化合物或其无毒盐或酸加成盐在制备预防和/或治疗活性或反应性星形细胞诱导的神经变性疾病的药物方面的用途:
其中n是0或1;
R11为氢或氯;
R5为R7-CH2-或R8,或
R5和R11一起为C3-10亚烷基;
R7为F-(CH2)m-,其中m为4-6、F3C-CH2-、被1或2个氯原子取代的C2-10烷基或被1或2个C1-4烷氧基、C3-7环烷基、苯基或苯氧基取代的C1-5烷基;
R8为
(i)C3-10烷基,
(ii)C3-10烯基,
(iii)C2-10烷氧基,
(iv)C2-10烷硫基,
(v)C3-7环烷基,
(vi)苯基或
(vii)苯氧基;
R6为羟基、C1-4烷氧基、被1个苯基取代的C1-4烷氧基或NR9R10,其中
R9和R10独立地代表
(i)氢,
(ii)C1-4烷基,
(iii)苯基,
(iv)被C1-4烷氧基或羧基取代的苯基,
(v)含1个氮原子的4-7元杂环或
(vi)被苯基取代的C1-4烷基、被C1-4烷氧基或羧基取代的苯基或含1个氮原子的4-7元杂环,或与其连接氮原子一起为含1或2个氮原子或1个氮原子和1个氧原子的4-7元饱和杂环或氨基酸残基。
2.根据权利要求1的用途,其中该神经变性疾病是活性或反应性星形细胞诱导的中风或外伤引起的神经元机能障碍。
3.根据权利要求1的用途,其中该神经变性疾病是活性或反应性星形细胞诱导的脑瘤。
4.根据权利要求1的用途,其中该神经变性疾病是活性或反应性星形细胞诱导的感染。
5.根据权利要求1的用途,其中该神经变性疾病是活性或反应性星形细胞诱导的脱神经髓鞘病。
6.根据权利要求1的用途,其中该疾病是活性或反应性星形细胞诱导的Alzheimer病、肌萎缩性脊髓侧索硬化、进行性核上麻痹、橄榄体脑桥小脑萎缩、多发性硬化、星形细胞瘤、脑膜炎、脑脓肿、Creutzfeldt-Jakob病或AIDS病性痴呆。
7.根据权利要求1的用途,该化合物为
7-氟-2-丙基庚酸,
8-氟-2-丙基辛酸,
9-氟-2-丙基壬酸,
5,5,5-三氟-2-丙基戊酸。
8.根据权利要求1的用途,该化合物为
2-丙基戊酸,
2-丙基庚酸,
2-丙基己酸,
2-丙基癸酸,
2-丙基辛酸,
2-丙基壬酸,
4-甲基-2-丙基戊酸,
5-甲基-2-丙基己酸,
7-甲基-2-丙基辛酸,
6-甲基-2-丙基庚酸,
5-乙基-2-丙基庚酸,
5,5-二甲基-2-丙基己酸,
6,6-二甲基-2-丙基庚酸,
2-乙基己酸,
2-氯-2-丙基戊酸。
9.根据权利要求1的用途,该化合物为
7-氯-2-丙基庚酸,
2-苯甲基戊酸,
2-(3-苯基丙基)戊酸,
6-苯基-2-丙基己酸,
5-苯氧基-2-丙基戊酸,
2-环己基甲基戊酸,
2-(2-环己基乙基)戊酸
5-环己基-2-丙基戊酸,
2-(2-乙氧基乙基)戊酸,
2-(2-甲氧基乙基)戊酸,
5-甲氧基-2-丙基戊酸,
5-乙氧基-2-丙基戊酸,
6-甲氧基-2-丙基己酸,
2-苯基戊酸,
2-苯氧基戊酸,
2-环戊基戊酸,
2-环己基戊酸,
2-戊硫基戊酸,
2-丙基-4-戊烯酸,
2-丙基-7-辛烯酸,
2-丙氧基戊酸,
2-乙氧基戊酸,
2-丁氧基戊酸,
2-戊氧基戊酸,
2-己氧基戊酸,
2-丙基-2-戊烯酸。
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP15433193 | 1993-06-01 | ||
JP154331/1993 | 1993-06-01 | ||
JP301067/1993 | 1993-11-05 | ||
JP30106793 | 1993-11-05 | ||
JP80982/1994 | 1994-03-28 | ||
JP8098294 | 1994-03-28 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94106203A Division CN1083419C (zh) | 1993-06-01 | 1994-06-01 | 戊酸衍生物,其制备方法,含该衍生物的药物组合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1322524A CN1322524A (zh) | 2001-11-21 |
CN1200703C true CN1200703C (zh) | 2005-05-11 |
Family
ID=27303447
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94106203A Expired - Fee Related CN1083419C (zh) | 1993-06-01 | 1994-06-01 | 戊酸衍生物,其制备方法,含该衍生物的药物组合物及其用途 |
CNB001270885A Expired - Fee Related CN1200703C (zh) | 1993-06-01 | 2000-09-08 | 戊酸衍生物的用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94106203A Expired - Fee Related CN1083419C (zh) | 1993-06-01 | 1994-06-01 | 戊酸衍生物,其制备方法,含该衍生物的药物组合物及其用途 |
Country Status (12)
Country | Link |
---|---|
US (5) | US6201021B1 (zh) |
EP (1) | EP0632008B1 (zh) |
JP (4) | JP2756756B2 (zh) |
KR (2) | KR100225299B1 (zh) |
CN (2) | CN1083419C (zh) |
AT (1) | ATE163006T1 (zh) |
CA (1) | CA2124784C (zh) |
DE (1) | DE69408373T2 (zh) |
DK (1) | DK0632008T3 (zh) |
ES (1) | ES2113574T3 (zh) |
GR (1) | GR3026076T3 (zh) |
TW (1) | TW248552B (zh) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0632008B1 (en) | 1993-06-01 | 1998-02-04 | Ono Pharmaceutical Co., Ltd. | Pentanoic acid derivatives |
US5672746A (en) | 1994-08-30 | 1997-09-30 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
US6300373B1 (en) | 1993-09-10 | 2001-10-09 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
IL121269A0 (en) | 1997-07-09 | 1998-01-04 | Dpharm Ltd | Compositions and methods for reversibly increasing permeability of biomembranes |
US6518311B2 (en) | 1997-07-09 | 2003-02-11 | D-Pharm Ltd. | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain |
IL124118A (en) * | 1998-04-16 | 2007-09-20 | Yissum Res Dev Co | Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, method for their synthesis and pharmaceutical compositions containing them |
TW509672B (en) * | 1998-05-12 | 2002-11-11 | Ono Pharmaceutical Co | Novel intermediate compounds and processes for the production of optical active octanoic acid derivatives |
HUP0102456A3 (en) | 1998-06-22 | 2003-07-28 | American Biogenetic Sciences | The use of valproic acid analog for the treatment and prevention of migraine and affective illness |
JP2000229854A (ja) * | 1999-02-15 | 2000-08-22 | Ito En Ltd | 虚血性神経細胞死治療・予防用脳室内投与剤、血管性痴呆症治療・予防用脳室内投与剤、並びに脳内手術時投与剤 |
TWI268921B (en) | 1999-02-18 | 2006-12-21 | Ono Pharmaceutical Co | A process for preparing (2R)-2-propyloctanoic acid |
US6969732B2 (en) * | 1999-04-12 | 2005-11-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Propylisopropyl acetic acid and propylisopropyl acetamide stereoisomers, a method for their synthesis and pharmaceutical compositions containing them |
KR20020008168A (ko) * | 1999-04-30 | 2002-01-29 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ace-2 억제 화합물 및 이의 사용 방법 |
US7045532B2 (en) | 1999-04-30 | 2006-05-16 | Millennium Pharmaceuticals, Inc. | ACE-2 modulating compounds and methods of use thereof |
EA002380B1 (ru) * | 1999-07-21 | 2002-04-25 | Российский Государственный Педагогический Университет Им. А.И.Герцена | Антиишемическое средство |
JP4706950B2 (ja) * | 2000-07-18 | 2011-06-22 | 小野薬品工業株式会社 | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 |
KR100759771B1 (ko) * | 2000-07-18 | 2007-10-04 | 오노 야꾸힝 고교 가부시키가이샤 | 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제 |
US20040176347A1 (en) * | 2001-07-18 | 2004-09-09 | Kaneyoshi Honjo | Agent for treatment of cerebral ischemic diseases |
DE10136842A1 (de) * | 2001-07-23 | 2003-02-13 | Schering Ag | GABA¶A¶-Rezeptor-Modulatoren mit NMDA-antagonistischer Aktivität |
EP1293205A1 (en) * | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
JPWO2003097851A1 (ja) * | 2002-05-15 | 2005-09-15 | 小野薬品工業株式会社 | 光学活性アルキルカルボン酸誘導体の製造方法 |
ATE540129T1 (de) * | 2002-11-22 | 2012-01-15 | Univ Johns Hopkins | Target zur therapie kognitiver behinderungen |
AU2003289782A1 (en) * | 2002-12-16 | 2004-07-09 | The University Of British Columbia | Valproic acid analogues and pharmaceutical compositions thereof |
US20070037882A1 (en) * | 2003-04-22 | 2007-02-15 | Astellas Pharma Inc. | Remedy for cerebral neurodegenerative diseases using ppar agonist |
US7589221B2 (en) | 2003-06-10 | 2009-09-15 | Ono Pharmaceutical Co., Ltd. | Process for producing (2R)-2-propyloctanoic acid and intermediate therefor |
WO2005005366A1 (ja) * | 2003-07-15 | 2005-01-20 | Ono Pharmaceutical Co., Ltd. | 分枝鎖カルボン酸化合物およびその用途 |
ES2284029T5 (es) | 2003-07-25 | 2012-02-17 | Prometic Biosciences Inc. | Preparación de sales metálicas de ácidos grasos de cadena media. |
US7928143B2 (en) | 2003-10-03 | 2011-04-19 | Ono Pharmaceutical Co., Ltd. | Method for preventing and/or treating neurodegenerative diseases |
CN1889941A (zh) * | 2003-10-03 | 2007-01-03 | 小野药品工业株式会社 | 包含(2r)-2-丙基辛酸作为活性成分的输液制剂 |
WO2005032535A1 (ja) | 2003-10-03 | 2005-04-14 | Ono Pharmaceutical Co., Ltd. | 神経再生促進剤 |
CA2540670A1 (en) * | 2003-10-03 | 2005-04-14 | Ono Pharmaceutical Co., Ltd. | Drug containing (2r)-2-propyloctanoic acid as the active ingredient |
WO2005032537A1 (en) * | 2003-10-03 | 2005-04-14 | Ono Pharmaceutical Co., Ltd. | Method for preventing and/or treating neurodegenerative diseases |
EP1741697B1 (en) | 2004-04-28 | 2012-12-19 | Ono Pharmaceutical Co., Ltd. | Crystal comprising (2r)-2-propyloctanoic acid and dibenzylamine |
WO2006043532A1 (ja) * | 2004-10-19 | 2006-04-27 | Ono Pharmaceutical Co., Ltd. | パーキンソン病治療剤 |
CN101056842A (zh) * | 2004-11-16 | 2007-10-17 | 默克公司 | 治疗中风的(2r)-2-丙基辛酸前药 |
JPWO2006075596A1 (ja) * | 2005-01-13 | 2008-06-12 | 株式会社クラレ | 2−アリルカルボン酸化合物の製造方法 |
JPWO2006098292A1 (ja) | 2005-03-15 | 2008-08-21 | 小野薬品工業株式会社 | 眼疾患治療剤 |
EP1900363A4 (en) | 2005-06-27 | 2010-01-13 | Ono Pharmaceutical Co | THERAPEUTIC AGENT AGAINST PAIN |
AU2006305309A1 (en) | 2005-10-18 | 2007-04-26 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis |
FR2892410B1 (fr) | 2005-10-21 | 2010-10-15 | Fabre Pierre Dermo Cosmetique | Nouveaux hydro-acides gras insatures et leur utilisation dermo cosmetologique |
JPWO2007072902A1 (ja) | 2005-12-22 | 2009-06-04 | 小野薬品工業株式会社 | 急性期脳梗塞治療剤 |
US9517221B2 (en) | 2006-03-09 | 2016-12-13 | Ono Pharmaceutical Co., Ltd. | (2R)-2-propyloctanoic acid for functional brain disease |
EP2015741A4 (en) * | 2006-05-04 | 2009-12-23 | Merck & Co Inc | HISTONE DESACETYLASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATION |
US20100035927A1 (en) * | 2007-01-23 | 2010-02-11 | Nagoya City University | Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia |
EP2457567B1 (en) * | 2007-09-19 | 2015-12-30 | Nagoya Industrial Science Research Institute | Agent having neurotrophic factor-like activity |
WO2009080722A2 (en) * | 2007-12-21 | 2009-07-02 | Crystax Pharmaceuticals, S.L. | Carboxylic derivatives for use in the treatment of cancer |
KR101891986B1 (ko) | 2010-11-02 | 2018-08-27 | 니폰 조키 세야쿠 가부시키가이샤 | 트랜스-2-데센산 유도체 및 이것을 함유하는 의약 |
GB201020133D0 (en) * | 2010-11-26 | 2011-01-12 | Royal Holloway & Bedford New College | Therapeutic use of compounds |
US8921533B2 (en) | 2011-07-25 | 2014-12-30 | Chromatin Technologies | Glycosylated valproic acid analogs and uses thereof |
EP2560008B1 (en) * | 2011-08-18 | 2016-11-30 | Korea Institute of Science and Technology | Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same |
CN102503803B (zh) * | 2011-10-20 | 2013-12-04 | 广东食品药品职业学院 | 一种有机酸化合物及其提取方法与应用 |
EP2830611B1 (en) | 2012-03-30 | 2016-04-27 | Nestec S.A. | 4-oxo-2-pentenoic acid and brain health |
AU2016279486B2 (en) | 2015-06-15 | 2021-04-01 | Nmd Pharma A/S | Compounds for use in treating neuromuscular disorders |
CN105712864B (zh) * | 2016-01-21 | 2017-12-08 | 湖北相和精密化学有限公司 | 一种5‑溴戊酸的制备方法 |
BR112019006429A2 (pt) | 2016-10-03 | 2019-06-25 | Brivention Pharmaceutical Shanghai Inc | composição compreendendo combinação de análogo de trh com ácido arúndico, e sal farmaceuticamente aceitável de ácido arúndico |
MX2019012050A (es) * | 2017-04-10 | 2020-08-17 | Vitaflo Int Ltd | Composicion para usar en el tratamiento de la epilepsia. |
US11730714B2 (en) | 2017-12-14 | 2023-08-22 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11591284B2 (en) | 2017-12-14 | 2023-02-28 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
US11147788B2 (en) | 2017-12-14 | 2021-10-19 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
CN111592459B (zh) * | 2020-06-28 | 2021-10-15 | 北京博萃循环科技有限公司 | 羧酸类化合物、其制备方法及应用 |
TW202228652A (zh) | 2020-10-02 | 2022-08-01 | 國立大學法人北海道大學 | 脂質奈米粒子 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE555319A (zh) | 1956-03-21 | 1900-01-01 | ||
US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
FR2442M (fr) * | 1962-10-17 | 1964-04-06 | Henry Eugene | L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central. |
US3487956A (en) | 1968-02-28 | 1970-01-06 | Smith Corp A O | Integral shield for discharge conveyor trough |
US3701729A (en) | 1970-06-01 | 1972-10-31 | Tenneco Chem | Oil-soluble mixed copper soap products |
US3847956A (en) | 1973-04-06 | 1974-11-12 | Us Agriculture | 2-hydroperoxycarboxylic acids and their preparation |
US3932285A (en) | 1973-10-03 | 1976-01-13 | Tenneco Chemicals, Inc. | Chromium salt compositions and a process for their production |
US4025649A (en) * | 1974-08-19 | 1977-05-24 | Labaz | Acetic acid derivatives having pharmacological activity and compositions containing the same |
US4129599A (en) | 1975-04-28 | 1978-12-12 | The Board Of Trustees Of Leland Stanford Jr. University | A-Norsteroids |
FR2383907A1 (fr) * | 1977-03-15 | 1978-10-13 | Labaz | Procede de preparation de derives de l'acide acetique et derives obtenus par ce procede |
JPS5680116A (en) | 1979-12-05 | 1981-07-01 | Sanyo Electric Co Ltd | Manufacture of substrate for magnetic bubble |
FR2470758A1 (fr) * | 1979-12-07 | 1981-06-12 | Sanofi Sa | Procede pour la fixation de groupes alkyles sur une chaine carbonee portant un groupe fonctionnel |
JPH0233704B2 (ja) | 1982-10-07 | 1990-07-30 | Takeda Chemical Industries Ltd | Chikanbinirukarubonsanjudotai |
US5017375A (en) | 1982-11-24 | 1991-05-21 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
FR2599737B1 (fr) | 1986-06-10 | 1989-05-19 | Sanofi Sa | Procede pour la fixation de groupes alkyles, alkenyles, cycloalkyles ou aralkyles sur une chaine carbonee portant un groupement fonctionnel |
EP0252736B1 (en) * | 1986-07-11 | 1991-07-24 | Sagami Chemical Research Center | Process for preparing fluorine-containing carboxylic acid ester |
US4923696A (en) | 1987-05-04 | 1990-05-08 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
US5202120A (en) | 1987-09-11 | 1993-04-13 | Case Western Reserve University | Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes |
US4900553A (en) | 1987-09-11 | 1990-02-13 | Case Western Reserve University | Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes |
JPH01135740A (ja) | 1987-11-24 | 1989-05-29 | Nippon Mining Co Ltd | 光学活性を有する2―アルキル―1―アルカン酸の製造方法 |
US5166317A (en) | 1988-10-31 | 1992-11-24 | Houston Biotechnology Incorporated | Neurotrophic factor |
US5011914A (en) | 1989-01-05 | 1991-04-30 | Collins Franklin D | Purified ciliary neurotrophic factor |
US4997929A (en) | 1989-01-05 | 1991-03-05 | Synergen, Inc. | Purified ciliary neurotrophic factor |
US5141856A (en) | 1989-01-05 | 1992-08-25 | Synergen, Inc. | Expression of purified ciliary neurotrophic factor |
US5215969A (en) | 1989-08-11 | 1993-06-01 | Hahnemann University | Dopaminergic neurotrophic factor for treatment of Parkinson's disease |
US5229500A (en) | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
US5180820A (en) | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
IE903130A1 (en) | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
US5021398A (en) | 1989-10-26 | 1991-06-04 | Amp Incorporated | Method of forming patterned oxide superconducting films |
US5235043A (en) | 1990-04-06 | 1993-08-10 | Synergen, Inc. | Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins |
US5426177A (en) | 1990-06-01 | 1995-06-20 | Regeneron Pharmaceuticals, Inc. | Ciliary neurotrophic factor receptor |
US5504197A (en) | 1990-06-20 | 1996-04-02 | The Salk Institute For Biological Studies | DNA encoding neurotrophic growth factors |
US5169764A (en) | 1990-08-08 | 1992-12-08 | Regeneron Pharmaceuticals, Inc. | Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras |
US5780587A (en) | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
US5364769A (en) | 1990-09-25 | 1994-11-15 | Genentech, Inc. | Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production |
FR2673942B1 (fr) | 1991-03-15 | 1994-09-09 | Sanofi Sa | Procede de preparation de l'acide (e)-propyl-2 pentene-2 ouique et composes intermediaires. |
US5229365A (en) | 1991-05-15 | 1993-07-20 | President And Fellows Of Harvard College | Endocrine cell stimulation by neurotrophic agents |
ATE162795T1 (de) | 1991-11-13 | 1998-02-15 | Consejo Superior Investigacion | Die mitose von astrozyten von tumorzellen des nervensystems hemmende oligosacharide und ein verfahren zu ihrer herstellung |
US5332672A (en) | 1991-12-02 | 1994-07-26 | Regeneron Pharmaceuticals, Inc. | Prevention of ES cell differentiation by ciliary neurotrophic factor |
US5346769A (en) * | 1991-12-26 | 1994-09-13 | Shell Oil Company | Process for preparing a prepeg comprising a resin derived from dialkenylbenzene and polyarylamine reactants |
AU3734693A (en) | 1992-03-17 | 1993-10-21 | Board Of Regents, The University Of Texas System | Neurotrophic peptides |
US5342942A (en) | 1992-06-09 | 1994-08-30 | Warner-Lambert Company | Pyrazoloquinazolone derivatives as neurotrophic agents |
US5360740A (en) | 1992-07-02 | 1994-11-01 | Regeneron Pharmaceuticals, Inc. | Assay system for degenerative muscle disease |
US5387520A (en) | 1992-08-27 | 1995-02-07 | Worcester Foundation For Experimental Biology | Treatment of tumor cells in vitro with neurotrophic factors and cell proliferation inhibitors |
DE4231085A1 (de) | 1992-09-12 | 1994-03-17 | Desitin Arzneimittel Gmbh | VPA-analoge Antiepileptika |
JPH06116200A (ja) | 1992-10-06 | 1994-04-26 | Kureha Chem Ind Co Ltd | 新規なフッ素化バルプロ酸誘導体及び抗てんかん剤 |
US5349056A (en) | 1992-10-09 | 1994-09-20 | Regeneron Pharmaceuticals | Modified ciliary neurotrophic factors |
US5340808A (en) | 1992-11-13 | 1994-08-23 | Warner Lambert Company | Fused pyridazinoquinazolone derivatives as neurotrophic agents |
CA2148101C (en) | 1992-11-30 | 1999-04-20 | Phillip Kyle Vinson | High sudsing detergent compositions with specially selected soaps |
JP3304459B2 (ja) | 1992-12-18 | 2002-07-22 | 松下電器産業株式会社 | 電解コンデンサ駆動用電解液およびそれを用いた電解コンデンサ |
CA2159738A1 (en) | 1993-04-13 | 1994-10-27 | Eugene O. Major | Use of neuro-derived fetal cell lines for transplantation therapy |
EP0632008B1 (en) | 1993-06-01 | 1998-02-04 | Ono Pharmaceutical Co., Ltd. | Pentanoic acid derivatives |
US5672746A (en) | 1994-08-30 | 1997-09-30 | American Biogenetic Sciences, Inc. | Antiproliferative and neurotrophic molecules |
-
1994
- 1994-05-30 EP EP94108330A patent/EP0632008B1/en not_active Expired - Lifetime
- 1994-05-30 DK DK94108330T patent/DK0632008T3/da active
- 1994-05-30 TW TW083104904A patent/TW248552B/zh active
- 1994-05-30 AT AT94108330T patent/ATE163006T1/de active
- 1994-05-30 DE DE69408373T patent/DE69408373T2/de not_active Expired - Lifetime
- 1994-05-30 ES ES94108330T patent/ES2113574T3/es not_active Expired - Lifetime
- 1994-05-31 CA CA002124784A patent/CA2124784C/en not_active Expired - Fee Related
- 1994-05-31 JP JP6140957A patent/JP2756756B2/ja not_active Expired - Fee Related
- 1994-06-01 KR KR1019940012261A patent/KR100225299B1/ko not_active IP Right Cessation
- 1994-06-01 CN CN94106203A patent/CN1083419C/zh not_active Expired - Fee Related
-
1996
- 1996-07-23 US US08/681,482 patent/US6201021B1/en not_active Expired - Lifetime
- 1996-07-31 JP JP8216932A patent/JP2826995B2/ja not_active Expired - Fee Related
-
1998
- 1998-01-29 JP JP10032255A patent/JP2935110B2/ja not_active Expired - Fee Related
- 1998-02-05 GR GR980400076T patent/GR3026076T3/el unknown
- 1998-06-04 JP JP15557798A patent/JP3195581B2/ja not_active Expired - Lifetime
-
1999
- 1999-02-26 KR KR1019990006501A patent/KR100253725B1/ko not_active IP Right Cessation
-
2000
- 2000-09-08 CN CNB001270885A patent/CN1200703C/zh not_active Expired - Fee Related
-
2002
- 2002-07-15 US US10/194,247 patent/US7176240B2/en not_active Expired - Fee Related
-
2005
- 2005-07-29 US US11/192,004 patent/US7569609B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,002 patent/US7569608B2/en not_active Expired - Fee Related
- 2005-07-29 US US11/192,003 patent/US20050267168A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2124784C (en) | 2003-01-07 |
JP3195581B2 (ja) | 2001-08-06 |
US7176240B2 (en) | 2007-02-13 |
JPH07316092A (ja) | 1995-12-05 |
JPH09118644A (ja) | 1997-05-06 |
DE69408373T2 (de) | 1998-07-16 |
ES2113574T3 (es) | 1998-05-01 |
ATE163006T1 (de) | 1998-02-15 |
GR3026076T3 (en) | 1998-05-29 |
US20050267167A1 (en) | 2005-12-01 |
US6201021B1 (en) | 2001-03-13 |
EP0632008B1 (en) | 1998-02-04 |
DK0632008T3 (da) | 1998-09-23 |
JP2756756B2 (ja) | 1998-05-25 |
US20050267168A1 (en) | 2005-12-01 |
CA2124784A1 (en) | 1994-12-02 |
DE69408373D1 (de) | 1998-03-12 |
CN1100408A (zh) | 1995-03-22 |
KR950000642A (ko) | 1995-01-03 |
JPH10324626A (ja) | 1998-12-08 |
KR100253725B1 (en) | 2000-04-15 |
JP2935110B2 (ja) | 1999-08-16 |
US20050261371A1 (en) | 2005-11-24 |
CN1083419C (zh) | 2002-04-24 |
JPH10204023A (ja) | 1998-08-04 |
EP0632008A1 (en) | 1995-01-04 |
US20030096802A1 (en) | 2003-05-22 |
US7569608B2 (en) | 2009-08-04 |
JP2826995B2 (ja) | 1998-11-18 |
KR100225299B1 (ko) | 1999-10-15 |
TW248552B (zh) | 1995-06-01 |
US7569609B2 (en) | 2009-08-04 |
CN1322524A (zh) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1200703C (zh) | 戊酸衍生物的用途 | |
CN1028227C (zh) | 药物活性的1,5-二芳基-3-取代吡唑的合成方法 | |
CN1157368C (zh) | 人过氧化物酶体增殖剂活化受体(PPAR)α激动剂-取代苯基丙酸衍生物 | |
CN1208319C (zh) | 2-氧代-1-吡咯烷衍生物、其制备方法和用途 | |
CN100338036C (zh) | 对激酶及细胞周期蛋白复合物具有抑制作用的取代的吲哚满酮 | |
CN1158277C (zh) | 具有哌啶结构的法尼转移酶抑制剂及其制备方法 | |
CN1225459C (zh) | 具有抗炎、止痛和抗血栓形成活性的硝基氧基衍生物 | |
CN1596249A (zh) | 苯并噁嗪与苯并噻嗪衍生物和含有它们的药物组合物 | |
CN1310872C (zh) | 单和双取代的3-丙基-γ-氨基丁酸 | |
CN1495160A (zh) | 1-取代-1-氨基甲基-环烷衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途 | |
CN1028529C (zh) | 内亚苯基氧杂双环庚基取代的前列腺素类似物的制法 | |
CN1479715A (zh) | 用于抑制由白介素8诱导的中性粒细胞趋化作用的酰胺 | |
CN101031289A (zh) | 作为具有降低胃肠毒性的治疗剂的吲哚乙酸和茚乙酸衍生物 | |
CN1697828A (zh) | 新颖的化合物和它们在医药中的用途、它们的制备方法与含有它们的药物组合物 | |
CN86105664A (zh) | 7-氧杂二环庚烷取代的二酰胺及其同种类的前列腺素类似物 | |
CN1298299A (zh) | 抗菌剂 | |
CN1112786A (zh) | 2-氨基-4-苯基-4-氧代丁酸衍生物 | |
CN1247577C (zh) | 螺环衍生物和以其作为有效成分的粘附分子抑制剂 | |
CN1217932C (zh) | 抗菌剂 | |
CN1170811C (zh) | 支链氨基酸依赖性氨基转移酶的抑制剂及其在治疗糖尿病性视网膜病中的应用 | |
CN1203058C (zh) | 哌啶衍生物及含这些衍生物作为有效成分的药物 | |
CN1277820C (zh) | 作为单胺氧化酶b的抑制剂的邻苯二甲酰亚氨基衍生物 | |
CN1325376A (zh) | 新型化合物及其医药用途 | |
CN1922137A (zh) | 蛋白酶抑制剂 | |
CN1489582A (zh) | 二氢化萘衍生物及包含该衍生物作为活性成分的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050511 Termination date: 20100601 |